

# FRENTE DIAGNÓSTICA E TERAPÊUTICA NA NEUROLOGIA 2

BENEDITO RODRIGUES DA SILVA NETO  
(ORGANIZADOR)



**Atena**  
Editora  
Ano 2020



# FRENTE DIAGNÓSTICA E TERAPÊUTICA NA NEUROLOGIA 2

BENEDITO RODRIGUES DA SILVA NETO  
(ORGANIZADOR)



**Atena**  
Editora  
Ano 2020

2020 by Atena Editora

Copyright © Atena Editora

Copyright do Texto © 2020 Os autores

Copyright da Edição © 2020 Atena Editora

**Editora Chefe:** Profª Drª Antonella Carvalho de Oliveira

**Diagramação:** Geraldo Alves

**Edição de Arte:** Lorena Prestes

**Revisão:** Os Autores



Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição *Creative Commons*. Atribuição 4.0 Internacional (CC BY 4.0).

O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

### **Conselho Editorial**

#### **Ciências Humanas e Sociais Aplicadas**

Profª Drª Adriana Demite Stephani – Universidade Federal do Tocantins

Prof. Dr. Álvaro Augusto de Borba Barreto – Universidade Federal de Pelotas

Prof. Dr. Alexandre Jose Schumacher – Instituto Federal de Educação, Ciência e Tecnologia de Mato Grosso

Prof. Dr. Antonio Carlos Frasson – Universidade Tecnológica Federal do Paraná

Prof. Dr. Antonio Gasparetto Júnior – Instituto Federal do Sudeste de Minas Gerais

Prof. Dr. Antonio Isidro-Filho – Universidade de Brasília

Prof. Dr. Carlos Antonio de Souza Moraes – Universidade Federal Fluminense

Prof. Dr. Constantino Ribeiro de Oliveira Junior – Universidade Estadual de Ponta Grossa

Profª Drª Cristina Gaio – Universidade de Lisboa

Profª Drª Denise Rocha – Universidade Federal do Ceará

Prof. Dr. Deyvison de Lima Oliveira – Universidade Federal de Rondônia

Prof. Dr. Edvaldo Antunes de Farias – Universidade Estácio de Sá

Prof. Dr. Eloi Martins Senhora – Universidade Federal de Roraima

Prof. Dr. Fabiano Tadeu Grazioli – Universidade Regional Integrada do Alto Uruguai e das Missões

Prof. Dr. Gilmei Fleck – Universidade Estadual do Oeste do Paraná

Profª Drª Ivone Goulart Lopes – Istituto Internazionale delle Figlie di Maria Ausiliatrice

Prof. Dr. Julio Candido de Meirelles Junior – Universidade Federal Fluminense

Profª Drª Keyla Christina Almeida Portela – Instituto Federal de Educação, Ciência e Tecnologia de Mato Grosso

Profª Drª Lina Maria Gonçalves – Universidade Federal do Tocantins

Profª Drª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte

Prof. Dr. Marcelo Pereira da Silva – Universidade Federal do Maranhão

Profª Drª Miranilde Oliveira Neves – Instituto de Educação, Ciência e Tecnologia do Pará

Profª Drª Paola Andressa Scortegagna – Universidade Estadual de Ponta Grossa

Profª Drª Rita de Cássia da Silva Oliveira – Universidade Estadual de Ponta Grossa

Profª Drª Sandra Regina Gardacho Pietrobon – Universidade Estadual do Centro-Oeste

Profª Drª Sheila Marta Carregosa Rocha – Universidade do Estado da Bahia

Prof. Dr. Rui Maia Diamantino – Universidade Salvador

Prof. Dr. Urandi João Rodrigues Junior – Universidade Federal do Oeste do Pará

Profª Drª Vanessa Bordin Viera – Universidade Federal de Campina Grande

Prof. Dr. William Cleber Domingues Silva – Universidade Federal Rural do Rio de Janeiro

Prof. Dr. Willian Douglas Guilherme – Universidade Federal do Tocantins

#### **Ciências Agrárias e Multidisciplinar**

Prof. Dr. Alexandre Igor Azevedo Pereira – Instituto Federal Goiano

Prof. Dr. Antonio Pasqualetto – Pontifícia Universidade Católica de Goiás

Profª Drª Daiane Garabeli Trojan – Universidade Norte do Paraná

Profª Drª Diocléa Almeida Seabra Silva – Universidade Federal Rural da Amazônia  
Prof. Dr. Écio Souza Diniz – Universidade Federal de Viçosa  
Prof. Dr. Fábio Steiner – Universidade Estadual de Mato Grosso do Sul  
Prof. Dr. Fágner Cavalcante Patrocínio dos Santos – Universidade Federal do Ceará  
Profª Drª Girlene Santos de Souza – Universidade Federal do Recôncavo da Bahia  
Prof. Dr. Júlio César Ribeiro – Universidade Federal Rural do Rio de Janeiro  
Profª Drª Lina Raquel Santos Araújo – Universidade Estadual do Ceará  
Prof. Dr. Pedro Manuel Villa – Universidade Federal de Viçosa  
Profª Drª Raissa Rachel Salustriano da Silva Matos – Universidade Federal do Maranhão  
Prof. Dr. Ronilson Freitas de Souza – Universidade do Estado do Pará  
Profª Drª Talita de Santos Matos – Universidade Federal Rural do Rio de Janeiro  
Prof. Dr. Tiago da Silva Teófilo – Universidade Federal Rural do Semi-Árido  
Prof. Dr. Valdemar Antonio Paffaro Junior – Universidade Federal de Alfenas

### **Ciências Biológicas e da Saúde**

Prof. Dr. André Ribeiro da Silva – Universidade de Brasília  
Profª Drª Anelise Levay Murari – Universidade Federal de Pelotas  
Prof. Dr. Benedito Rodrigues da Silva Neto – Universidade Federal de Goiás  
Prof. Dr. Edson da Silva – Universidade Federal dos Vales do Jequitinhonha e Mucuri  
Profª Drª Eleuza Rodrigues Machado – Faculdade Anhanguera de Brasília  
Profª Drª Elane Schwinden Prudêncio – Universidade Federal de Santa Catarina  
Prof. Dr. Ferlando Lima Santos – Universidade Federal do Recôncavo da Bahia  
Prof. Dr. Gianfábio Pimentel Franco – Universidade Federal de Santa Maria  
Prof. Dr. Igor Luiz Vieira de Lima Santos – Universidade Federal de Campina Grande  
Prof. Dr. José Max Barbosa de Oliveira Junior – Universidade Federal do Oeste do Pará  
Profª Drª Magnólia de Araújo Campos – Universidade Federal de Campina Grande  
Profª Drª Mylena Andréa Oliveira Torres – Universidade Ceuma  
Profª Drª Natiéli Piovesan – Instituto Federaci do Rio Grande do Norte  
Prof. Dr. Paulo Inada – Universidade Estadual de Maringá  
Profª Drª Vanessa Lima Gonçalves – Universidade Estadual de Ponta Grossa  
Profª Drª Vanessa Bordin Viera – Universidade Federal de Campina Grande

### **Ciências Exatas e da Terra e Engenharias**

Prof. Dr. Adélio Alcino Sampaio Castro Machado – Universidade do Porto  
Prof. Dr. Alexandre Leite dos Santos Silva – Universidade Federal do Piauí  
Prof. Dr. Carlos Eduardo Sanches de Andrade – Universidade Federal de Goiás  
Profª Drª Carmen Lúcia Voigt – Universidade Norte do Paraná  
Prof. Dr. Eloi Rufato Junior – Universidade Tecnológica Federal do Paraná  
Prof. Dr. Fabrício Menezes Ramos – Instituto Federal do Pará  
Prof. Dr. Juliano Carlo Rufino de Freitas – Universidade Federal de Campina Grande  
Prof. Dr. Marcelo Marques – Universidade Estadual de Maringá  
Profª Drª Neiva Maria de Almeida – Universidade Federal da Paraíba  
Profª Drª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte  
Prof. Dr. Takeshy Tachizawa – Faculdade de Campo Limpo Paulista

### **Conselho Técnico Científico**

Prof. Msc. Abrãao Carvalho Nogueira – Universidade Federal do Espírito Santo  
Prof. Msc. Adalberto Zorzo – Centro Estadual de Educação Tecnológica Paula Souza  
Prof. Dr. Adailson Wagner Sousa de Vasconcelos – Ordem dos Advogados do Brasil/Seccional Paraíba  
Prof. Msc. André Flávio Gonçalves Silva – Universidade Federal do Maranhão  
Profª Drª Andreza Lopes – Instituto de Pesquisa e Desenvolvimento Acadêmico  
Profª Msc. Bianca Camargo Martins – UniCesumar  
Prof. Msc. Carlos Antônio dos Santos – Universidade Federal Rural do Rio de Janeiro  
Prof. Msc. Cláudia de Araújo Marques – Faculdade de Música do Espírito Santo  
Prof. Msc. Daniel da Silva Miranda – Universidade Federal do Pará  
Profª Msc. Dayane de Melo Barros – Universidade Federal de Pernambuco



Prof. Dr. Edwaldo Costa – Marinha do Brasil  
 Prof. Msc. Eliel Constantino da Silva – Universidade Estadual Paulista Júlio de Mesquita  
 Prof. Msc. Gevair Campos – Instituto Mineiro de Agropecuária  
 Prof. Msc. Guilherme Renato Gomes – Universidade Norte do Paraná  
 Prof<sup>a</sup> Msc. Jaqueline Oliveira Rezende – Universidade Federal de Uberlândia  
 Prof. Msc. José Messias Ribeiro Júnior – Instituto Federal de Educação Tecnológica de Pernambuco  
 Prof. Msc. Leonardo Tullio – Universidade Estadual de Ponta Grossa  
 Prof<sup>a</sup> Msc. Lilian Coelho de Freitas – Instituto Federal do Pará  
 Prof<sup>a</sup> Msc. Liliani Aparecida Sereno Fontes de Medeiros – Consórcio CEDERJ  
 Prof<sup>a</sup> Dr<sup>a</sup> Lívia do Carmo Silva – Universidade Federal de Goiás  
 Prof. Msc. Luis Henrique Almeida Castro – Universidade Federal da Grande Dourados  
 Prof. Msc. Luan Vinicius Bernardelli – Universidade Estadual de Maringá  
 Prof. Msc. Rafael Henrique Silva – Hospital Universitário da Universidade Federal da Grande Dourados  
 Prof<sup>a</sup> Msc. Renata Luciane Polsaque Young Blood – UniSecal  
 Prof<sup>a</sup> Msc. Solange Aparecida de Souza Monteiro – Instituto Federal de São Paulo  
 Prof. Dr. Welleson Feitosa Gazel – Universidade Paulista

**Dados Internacionais de Catalogação na Publicação (CIP)  
(eDOC BRASIL, Belo Horizonte/MG)**

F879 Frente diagnóstica e terapêutica na neurologia 2 [recurso eletrônico] /  
Organizador Benedito Rodrigues da Silva Neto. – Ponta Grossa  
PR: Atena Editora, 2020.

Formato: PDF  
 Requisitos de sistema: Adobe Acrobat Reader  
 Modo de acesso: World Wide Web  
 Inclui bibliografia  
 ISBN 978-85-7247-956-1  
 DOI 10.22533/at.ed.561202801

1. Neurologia. 2. Diagnóstico. 3. Sistema nervoso – Doenças.  
 I. Silva Neto, Benedito Rodrigues da.

CDD 616.8

**Elaborado por Maurício Amormino Júnior | CRB6/2422**

Atena Editora  
 Ponta Grossa – Paraná - Brasil  
[www.atenaeditora.com.br](http://www.atenaeditora.com.br)  
[contato@atenaeditora.com.br](mailto:contato@atenaeditora.com.br)

## APRESENTAÇÃO

Apresentamos o segundo volume do livro “Frente Diagnóstica e Terapêutica na Neurologia”, um material rico e direcionado à todos acadêmicos e docentes da área da saúde com interesse em neurologia e áreas afins.

A especialidade médica responsável por trabalhar e analisar os distúrbios estruturais do sistema nervoso é denominada como neurologia. Do diagnóstico à terapêutica, todas as enfermidades que envolvem o sistema nervoso central, periférico, autônomo, simpático e parassimpático, são estudadas pelos profissionais com especialização em neurologia. Além das doenças neuropsicopatológicas, o CID divide as patologias do sistema nervoso em dez grupos com fins de análise epidemiológica.

Assim abordamos aqui assuntos relativos aos avanços e dados científicos aplicados aos estudos de base diagnóstica e terapêutica nesse reamo tão interessante da medicina, oferecendo um breve panorama daquilo que tem sido feito no país. Neste segundo volume o leitor poderá se aprofundar em temas relacionados ao Alzheimer, Hospitalização, Atenção Primária à Saúde, Apraxia, Demencia, Cognição, Neuropsicologia, Esclerose lateral amiotrófica, VIH tipo I, Parkinson, Epidemiologia, Indicadores de Morbimortalidade, Melanoma, Metástase, Neurossarcoidose, Endocardite bacteriana, Oligodendroglioma, Epilepsia Refratária, Tumor Cerebral Primário, Lobectomia Temporal Anterior e Doenças Neurodegenerativas como um todo.

Esperamos que o conteúdo deste material possa somar de maneira significativa ao conhecimento dos profissionais e acadêmicos, influenciando e estimulando cada vez mais a pesquisa nesta área em nosso país. Parabenizamos cada autor pela teoria bem fundamentada aliada à resultados promissores, e principalmente à Atena Editora por permitir que o conhecimento seja difundido em todo território nacional.

Desejo à todos uma ótima leitura!

Benedito Rodrigues da Silva Neto



## SUMÁRIO

<b>CAPÍTULO 1 .....</b>	<b>1</b>
<b>A DOENÇA DE ALZHEIMER NO CENÁRIO HOSPITALAR DO BRASIL DE 2013 A 2017: ASPECTOS EPIDEMIOLÓGICOS</b>	
Maykon Wanderley Leite Alves da Silva	
José Victor de Mendonça Silva	
Mayara Leite Alves da Silva	
Georgianna Silva Wanderley	
Geordanna Silva Wanderley	
Nycolas Emanuel Tavares de Lira	
Jamyly Ferreira Targino Silva	
Alexandre Otilio Pinto Júnior	
Quitéria Maria Wanderley Rocha	
<b>DOI 10.22533/at.ed.5612028011</b>	
<b>CAPÍTULO 2 .....</b>	<b>8</b>
<b>ANÁLISE DO CONTEÚDO DE SONHOS DURANTE O CICLO MENSTRUAL</b>	
Euclides Maurício Trindade Filho	
Anie Deomar Dalboni França	
Júlia Badra Nogueira Alves	
Juliana Felizardo Viana	
Natália Lima Andrade	
Maysa Tavares Duarte de Alencar	
Camila Maria Beder Ribeiro Girish Panjwani	
Aleska Dias Vanderlei	
Morgana Rolemberg de Melo	
Leonardo Coelho de Mendonça Silva	
Paulo José Medeiros de Souza Costa	
Lousane Leonoura Alves Santos	
<b>DOI 10.22533/at.ed.5612028012</b>	
<b>CAPÍTULO 3 .....</b>	<b>18</b>
<b>ANÁLISE QUANTITATIVA DE HOSPITALIZAÇÕES POR AVC EM PERNAMBUCO NOS ÚLTIMOS 20 ANOS</b>	
Gabriela Lacourt Rodrigues	
Cibele Cerqueira Brito	
Caio Augusto Carneiro da Costa	
Carolina de Moura Germoglio	
Larissa Neves de Lucena	
Leonardo Meira de Carvalho	
Lucas Ferreira de Lins	
Maria Eduarda de Oliveira Fernandes	
Mateus Santiago de Souza	
Abel Barbosa de Araújo Gomes	
Wendell Duarte Xavier	
Nereu Alves Lacerda	
<b>DOI 10.22533/at.ed.5612028013</b>	
<b>CAPÍTULO 4 .....</b>	<b>26</b>
<b>AVALIAÇÃO DA BIODISPONIBILIDADE DE CANABIDIOL EM VOLUNTÁRIOS SAUDÁVEIS</b>	
Liberato Brum Junior	
Patrícia Moura da Rosa Zimmermann	

Emanuelle Menegazzo Webler  
Volnei José Tondo Filho  
Letícia Mello Rechia  
José Alexandre de Souza Crippa  
Jaime Eduardo Cecílio Hallak  
Antônio Waldo Zuardi

**DOI 10.22533/at.ed.5612028014**

**CAPÍTULO 5 ..... 32**

**CROSSED CEREBELLAR DIASCHISIS IN A PATIENT WITH CORTICOBASAL SYNDROME IN THE NORTHEAST OF BRAZIL**

José Wagner Leonel Tavares Júnior  
José Ibiapina Siqueira Neto  
Gilberto Sousa Alves  
José Daniel Vieira De Castro  
Pedro Braga Neto

**DOI 10.22533/at.ed.5612028015**

**CAPÍTULO 6 ..... 35**

**DEMÊNCIA COM CORPOS DE LEWY: RELATO DE CASO E DISCUSSÃO**

Caio Augusto Carneiro da Costa  
Nereu Alves Lacerda  
Rodolpho Douglas Pimenta de Araújo  
André Henrique Mororó Araújo  
Gabriela Lacourt Rodrigues  
Larissa Neves de Lucena  
Leonardo Meira de Carvalho  
Lucas Germano Figueiredo Vieira  
Lucas Ferreira Lins  
Maria Eduarda de Oliveira Fernandes  
Mateus Santiago de Souza  
Wendell Duarte Xavier

**DOI 10.22533/at.ed.5612028016**

**CAPÍTULO 7 ..... 41**

**DISTÚRPIO DO SONO EM UM CASO DE DEMÊNCIA FRONTOTEMPORAL**

Valéria Figueiredo Fraga  
Heitor Constantino Gomes Fraga

**DOI 10.22533/at.ed.5612028017**

**CAPÍTULO 8 ..... 47**

**EFFECTS OF ANTIEPILEPTIC DRUGS ON SPREADING DEPRESSION IN THE CHICK RETINA: IMPLICATIONS FOR MIGRAINE PROPHYLAXIS**

João Baptista Mascarenhas de Moraes Neto  
Hiss Martins- Ferreira  
Jean Christopher Houzel  
Lenny Abreu Cavalcante  
Gilmar da Silva Aleixo  
Arthur Ferrer Melo  
Eduardo Fonseca

**DOI 10.22533/at.ed.5612028018**



**CAPÍTULO 9 ..... 86**

**ENCEFALITE AUTOIMUNE ANTI-NMDAR EM ADOLESCENTE: RELATO DE CASO**

Caroline Moraes Tapajós Bolzani  
Mariana de Almeida Vidal  
Renato Buarque Pereira  
Maycon Melo Lopes  
Iure Belli de Melo  
Carla Nakao Nonato  
Paulo Vitor Castro Perin  
Helen Maia Tavares de Andrade  
Marília Mamprim de Morais Perin

**DOI 10.22533/at.ed.5612028019**

**CAPÍTULO 10 ..... 93**

**ESCLEROSE LATERAL AMIOTRÓFICA EM PACIENTE COM VIH TIPO I. RELATO DE CASO**

Raquel Libanesa Rosario Beltré  
Karina Lebeis Pires  
Débora Coelho de Souza de Oliveira  
Caroline Bittar Braune

**DOI 10.22533/at.ed.56120280110**

**CAPÍTULO 11 ..... 98**

**ESTUDO EPIDEMIOLÓGICO ACERCA DA MORBIMORTALIDADE DA DOENÇA DE PARKINSON EM ALAGOAS E NO NORDESTE BRASILEIRO**

Carlos Henrique Silva de Melo  
João Pedro Matos de Santana  
Arsênio Jorge Ricarte Linhares  
Camila Farias Mota  
Gabriel Marcelo Rego de Paula  
Diego Armando Coimbra de Melo  
Érika Santos Machado  
Amanda Alves Leal da Cruz  
Matheus Santos Freitas  
Rafaella Fernanda de Farias Lima

**DOI 10.22533/at.ed.56120280111**

**CAPÍTULO 12 ..... 105**

**EXPOSIÇÃO À ATIVIDADE DE RISCO E PRINCIPAL SINTOMA EM PACIENTES COM CITOPTOCOCOSE EM UM HOSPITAL DE ENSINO EM MATO GROSSO DO SUL**

Isadora Mota Coelho Barbosa  
Rosianne Assis de Souza Tsujisaki  
Marilene Rodrigues Chang  
Amanda Borges Colman

**DOI 10.22533/at.ed.56120280112**

**CAPÍTULO 13 ..... 112**

**ÍNDICE DE HOSPITALIZAÇÃO POR ACIDENTE VASCULAR ENCEFÁLICO EM UM HOSPITAL PÚBLICO NA AMAZÔNIA BRASILEIRA**

Leandro Araújo Costa  
Leandro Ribeiro Barros Lima

Victor Paes Rodrigues  
Dicleidson Luiz da Silva Costa  
Rafael Nôvo Guerreiro  
Márcio Alex Reis Câmara  
Lianara de Souza Mindelo Autrn  
Juliana Henrique dos Reis  
Ana Claudia dos Santos Rodrigues  
Ádria Cristhellen de Jesus Costa  
Silvio Henrique dos Reis Júnior

**DOI 10.22533/at.ed.56120280113**

**CAPÍTULO 14 ..... 120**

**MELANOMA METASTÁTICO DIAGNOSTICADO DEVIDO A ACOMETIMENTO DA BAINHA DO NERVO ÓPTICO: UM RELATO DE CASO**

Rômulo Tscherbakowski Nunes de Guimarães Mourão  
Jose Antonio Lima Vieira  
Tácito Tscherbakowski Nunes de Guimarães Mourão  
Paula Reis Guimarães  
Isabella Cristina Tristão Pinto

**DOI 10.22533/at.ed.56120280114**

**CAPÍTULO 15 ..... 126**

**MUTAÇÃO NO CROMOSSOMO CDKL5 E SUAS MANIFESTAÇÕES CLÍNICAS**

Taciane Cezar de Albuquerque  
Jerônimo Cesar Ferreira Barcellos  
Camila Sugui  
Beatriz do Amaral Rezende Bento  
Sofia Amaral Rezende Diniz  
Jocikeli Lira Fonteles

**DOI 10.22533/at.ed.56120280115**

**CAPÍTULO 16 ..... 134**

**NEUROSARCOIDOSE: RELATO DE CASO EM PACIENTE COM REBAIXAMENTO DO SENSÓRIO ASSOCIADO A NEUROPATIA DE NERVO CRANIANO, CEFALIA E VASCULOPATIA**

Mariana Beiral Hämmerle  
Gabriela Antunes Martins de Souza  
Daiane Vieira Botelho  
Felipe Schmidt Ribeiro  
Gabriela Regina Accioly de Amorim Lopes  
Tatiana Lins de Miranda  
Francisco Ramon Canale Ferreira  
Claudia Cristina Ferreira Vasconcelos

**DOI 10.22533/at.ed.56120280116**

**CAPÍTULO 17 ..... 137**

**THE PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN IMMUNOCOMPETENT PATIENTS A CLINICAL CASE WITH GOOD EVOLUTION**

Talita Mota Almeida Brum  
Julian Euclides Mota Almeida

**DOI 10.22533/at.ed.56120280117**



<b>CAPÍTULO 18</b> .....	<b>139</b>
RELATO DE CASO: PACIENTE COM EPILEPSIA REFRATÁRIA ASSOCIADA A OLIGODENDROGLIOMA	
Mauricio Vaillant Amarante Ozinelia Pedroni Batista Camila Lampier Lutzke Shirley Kempin Quiqui	
<b>DOI 10.22533/at.ed.56120280118</b>	
<b>CAPÍTULO 19</b> .....	<b>146</b>
RELATO DE CASO: PACIENTE COM EPILEPSIA REFRATÁRIA ASSOCIADA A ESCLEROSE MESIAL HIPOCAMPAL DIREITA	
Mauricio Vaillant Amarante Ozinelia Pedroni Batista Camila Lampier Lutzke Shirley Kempin Quiqui	
<b>DOI 10.22533/at.ed.56120280119</b>	
<b>CAPÍTULO 20</b> .....	<b>152</b>
PERFIL EPIDEMIOLÓGICO DA MENINGITE NA POPULAÇÃO PEDIÁTRICA DAS MACRORREGIÕES BRASILEIRAS ENTRE 2010-2017	
Alana Oliveira Santos Felipe Reynan Vieira Paiva dos Santos Lívia de Almeida Andrade	
<b>DOI 10.22533/at.ed.56120280120</b>	
<b>CAPÍTULO 21</b> .....	<b>159</b>
PERFIL EPIDEMIOLÓGICO DAS INTERNAÇÕES POR EPILEPSIA NA BAHIA ENTRE O PERÍODO DE 2006 A 2016	
Victor Ribeiro da Paixão	
<b>DOI 10.22533/at.ed.56120280121</b>	
<b>CAPÍTULO 22</b> .....	<b>181</b>
PERFIL EPIDEMIOLÓGICO DOS PACIENTES COM ESCLEROSE MÚLTIPLA DA FACULDADE DE MEDICINA DO ABC	
Raphael Vinícius Gonzaga Vieira Margarete de Jesus Carvalho	
<b>DOI 10.22533/at.ed.56120280122</b>	
<b>CAPÍTULO 23</b> .....	<b>188</b>
RELATO DE CASO: DOENÇA DE WILSON COM EVOLUÇÃO ATÍPICA	
Rawanderson dos Santos André Limeira Tenório de Albuquerque Mariana Reis Prado	
<b>DOI 10.22533/at.ed.56120280123</b>	
<b>CAPÍTULO 24</b> .....	<b>195</b>
SÍNDROME DA DELEÇÃO DO CROMOSSOMO 18Q	
Taciane Cezar de Albuquerque Jerônimo Cesar Ferreira Barcellos	

Camila Sugui  
Beatriz do Amaral Rezende Bento  
Sofia Amaral Rezende Diniz  
Juliana Pimenta dos Reis Pereira Barros

**DOI 10.22533/at.ed.56120280124**

**CAPÍTULO 25 ..... 203**

**SÍNDROME DA MÃO ALIENÍGENA: UM RELATO DE CASO**

Anie Deomar Dalboni França  
Rafaella Cavalcante Medeiros Sousa  
Júlia Badra Nogueira Alves  
Juliana Felizardo Viana  
Natália Lima Andrade  
Camila Maria Beder Ribeiro Girish Panjwani  
Aleska Dias Vanderlei  
Morgana Rolemberg de Melo  
Paulo José Medeiros de Souza Costa  
Lousane Leonoura Alves Santos  
Lorella Marianne Chiappetta  
Euclides Mauricio Trindade Filho

**DOI 10.22533/at.ed.56120280125**

**CAPÍTULO 26 ..... 212**

**SÍNDROME DE STURGE-WEBER ACOMPANHADA DE ALOPECIA: UMA NOVA APRESENTAÇÃO CLÍNICA?**

Márcio Alves da Cruz Júnior  
Raissa Poletto Maluf  
Jeferson Santiago  
Heron Fernando de Sousa Gonzaga

**DOI 10.22533/at.ed.56120280126**

**CAPÍTULO 27 ..... 220**

**MANEJO CIRÚRGICO DA ENDOCARDITE INFECCIOSA COMPLICADA COM HEMORRAGIA SUBARACNOIDEA: RELATO DE CASO**

Rônney Pinto Lopes  
Natalia Trombini Mendes  
Lohana Santana Almeida da Silva  
Luiza Ramos de Freitas  
Moisés Antonio de Oliveira  
Paulo Diego Santos Silva  
Francisco Tomaz Meneses de Oliveira  
Rubens José Gagliardi

**DOI 10.22533/at.ed.56120280127**

**SOBRE O ORGANIZADOR..... 230**

**ÍNDICE REMISSIVO ..... 231**



## EFFECTS OF ANTIPILEPTIC DRUGS ON SPREADING DEPRESSION IN THE CHICK RETINA: IMPLICATIONS FOR MIGRAINE PROPHYLAXIS

*Data de aceite: 14/01/2020*

### **João Baptista Mascarenhas de Moraes Neto**

Lab. Neurobiologia do Desenvolvimento, IBCCF,  
UFRJ

Lab. Fronteiras em Neurociências, ICB, UFRJ

### **Hiss Martins- Ferreira**

Lab. Neurobiologia do Desenvolvimento, IBCCF,  
UFRJ

### **Jean Cristopher Houzel**

Lab. Fronteiras em Neurociências, ICB, UFRJ

### **Lenny Abreu Cavalcante**

Lab. Neurobiologia do Desenvolvimento, IBCCF,  
UFRJ

### **Gilmar da Silva Aleixo**

Fac. Medicina. UFRJ / Macaé.

### **Arthur Ferrer Melo**

Fac. Medicina. UFRJ / Macaé.

### **Eduardo Fonseca**

Fac. Medicina. UFRJ / Macaé.

**ABSTRACT:** Background: The Spreading Depression (SD) is an answer of the nervous tissue to a different type of local stimulus. It was described initially in the cortex of anesthetized rabbit and characterizes by a depression of the spontaneous electric and provoked activity, which initiate in the stimulated point and propagates, at the rate of 3.0-5.0 mm.min<sup>-1</sup>, for adjacent regions of the cerebral cortex. The eletrocorticographyc

period of activity depression belongs to 2-5 min and the re-establishment of the normal activity occurs in 15-20 min after the beginning of the reaction. The gear of this wave does not respect the limits of different vascular territories in the cortex and neither citoarchitectural differences nor functional differences. The knolled of this phenomenon is fundamental for the correct knowledge and treatment migraine (MG). Methods: In the present study, we analyze the effects of antiepileptic drugs (AED), also used in migraine (MG) prophylaxis, on the spreading depression (SD) in isolated retina of chick' (Gallus gallus domesicus). We studied five drugs with proven effect on the modulation of GABAergic transmission: Topiramate (TP), Valproate semisodium (VS), Gabapentin (GP), Lamotrigine (LT) and Levetiracetam (LV). Chicks' retinas were kept at 30-31°C in superfusion chamber, with a flow of 1,0 – 1,8 ml/min. of a Ringer's reference solution, and the reaction was evoked by mechanical and chemical stimulus, every 15 minutes. Using this model, we first measured the speed (mm/min.), the amplitude (mV), the deflagration threshold (after chemical stimulus with KCl-) and the absolute refractory period (sec.) of the SD, with and without the drugs used in the study. Subsequently, the speed and amplitude parameters, also with and without the drugs in study, were analyzed in an in vivo model. In

addition, the GABA-transaminase enzyme (GABA-T) activity was determined, with and without the drugs in study. Analysis of variance was used to determine the activity of GABA-transaminase (GABA-T). Results: We verified that all the drugs, particularly Topiramate (TP), reduce the speed and amplitude in a dose-dependent and reversed manner, in vitro as well as in vivo. All the drugs also increase, in a reversible form, the deflagration threshold for the SD, after chemical stimulus with KC-, in specific concentrations. It was also verified, that all the drugs increase, in a reversible form, the absolute refractory period. Topiramate (TP) was considered the most effective drug in the context of the proposed parameters. Levetiracetam (LV), in spite of its sui generis mechanism of action, was considered the less effective drug. The enzyme GABA-transaminase (GABA-T) displayed slight decrease activity, in the presence of Topiramate (TP), Valproate semisodium (VS) and Gabapentin (GP).

**KEYWORDS:** Migraine, Spreading Depression, Antiepileptic drugs, Neuropharmacology, Retina

## CONCLUSIONS

These results reinforce the notion that SD is a subjacent and relevant factor for the pathophysiology of migraine (MG), the treatment of this pathology must emphasize the use of antiepileptic drugs (AED), in special Topiramate (TP).

Antiepileptic drugs, and more especially Topiramate, can significantly affect both the threshold and the propagation of SD in a dose-dependent manner. Our results reinforce the notion that SD may underlie the physiopathology of migraine and that, although further investigations on cortical SD are needed, our model may be a useful tool for the test of new prophylactic drugs.

Cortical spreading depression was first described in 1943 by the Brazilian neurophysiologist Aristides Leão, during his PhD fellowship in physiology at Harvard University. In 1944, Leão published a paper entitled "Spreading depression of activity in the cerebral cortex", subsequently known internationally as Leão's spreading depression (Leão, 1944a).

Several studies indicate that spreading depression (SD) is fundamentally related to seizures marches and to aura of classical migraine. Others more recent studies, moreover call attention to its possible relevance in clinical disturbance associated with brain ischemia, trauma and hypoglycemia (Avoli and cols., 1991; Strong and cols., 2002). However, studies concerning the effect of antiepileptic drugs (AED) on the reaction are scarce. The importance of such studies was first shown by Woodbury (Woodbury, D.M., 1978) who pointed out their interest not only in terms of developing a model for evaluation of antiepileptic drugs but also in terms of their heuristic value in SD.

SD is defined as a slowly moving depression of cortical activity, is characterized

by a transient, slowly propagating depression of electroencephalographic activity (EEG), a marked reduction of the sensory and other evoked potentials, a negative slow potential change, a rise in tissue electrical impedance and some translocations of ion and water between the intra and extracellular compartments. Typically propagated at 2-3 mm per minute and, if conditions are appropriate and uniform in surrounding cortex, it proceeds in all directions from the point of origin (Do Carmo, R.J. and Martins-Ferreira, H, 1984; Hansen, A.J. and Olsen, C.E., 1980; Mori, S., Miller, W.H. and Tomita, T., 1976 ; Nicholson, C., Bruggencate, G., Stockle, H. And Steinberg R., 1978; Marshall, 1959). The propagation of the Leão's wave does not respect the limits of different vascular territories in the cortex, neither different citoarchitectural nor functional variances of the cortex (Somjen, 2001; Gorji, 2001).

The fact that a lot of animal species are susceptible to SD may have a significance explained by the phylogenetic conservation of the phenomenon (Bûres, 1974). This considerations, in addition to the other characteristics of the phenomenon; allow us to considerate the SD as a property inherent of the nervous system.

The main characteristics of spreading depression (SD) are a decrease of spontaneous electrical activity, slow negative potential changes, trans membrane ion translocations and an increase in tissue lactate (Leão, 1947; Martins-Ferreira, H. 1994).

The velocity of propagation has been measured and some physical and chemical factors underlying the spread of the electrophysiological depression have been identified however, some experimental studies have shown outstanding local reversible features of SD: 1. Decrease of "spontaneous" and evoked electrical cortical responses; 2. Extracellular negative slow-voltage variations (SVV); 3. Overflow of K<sup>+</sup> into the extracellular space concomitant with depletion of Ca<sup>2+</sup> and 4. Increase of intracellular Na<sup>+</sup>, Cl<sup>-</sup> and water (Kaig & Nicholson, 1978; Lauritzen, 1978; Leão, 1987; Van Harreveld, 1959; Vysckocil e cols. 1972).

The first hypothesis of the mechanism of propagation of SD was made by B. Grafstein in 1956 who postulate that the liberation of K<sup>+</sup> from cortical neurons as a result of intense activity or some other humoral or traumatic stimuli caused an increase of these ions in the extracellular space sufficient to depolarize adjacent neurons which, being thus stimulated to activity liberated a further quantity of potassium (Grafstein, 1963). In 1959, Van Harreveld suggests the glutamaergic hypothesis of propagation of SD. When applied for a short time, L-glutamate may trigger light scattering areas but there is no limit between excitatory and toxic effects (Van Harreveld and Fifková, 1970). This fact have been recently re-examined by Scheller e cols. in 1993 (Scheller and cols., 1993) using a microdialysis technique to measure amino acids release during cortical SD in anesthetized rats. Based on their observations and on literature on NMDA receptors, they concluded that glutamate release has indeed occurred in



the site where KCl- elicited the SD but, on the other regions of the cortex, it has indeed occurred but could not be detected by the technique employed ( Scheller and cols.,1993).

Retinal spreading depression is a very useful model for this phenomenon, has been extensively studied in terms of its optical, electrical and mechanical components. Ionic changes in the extracellular microenvironment have also been assessed and chemical substances liberated from tissue have been detected (Gouras, P, 1958; Martins-Ferreira, H.1962).

Two conspicuous characteristics make the avian retina in vitro a preparation of choice for experimental studies of the basic aspects of SD: 1. the anatomical localization of its cellular elements permits the isolation of a slice of neural tissue with less damage than if using any other from the Central Nervous System (CNS), 2. Due to the “inverted” position of its receptor cells, the pars nervosa has to be relatively transparent to visible light. These properties, in special the transparency, are a simple and useful method for judging the health of the retina preparation and studying the SD. Mechanical and chemical (KCl- solution) stimulus in the fragment of retina are easily detected. With the appropriate Ringer solution using in the preservation of the retina in healthy conditions, the SD could be seen with the unaided eye or under a low-power microscope as an enlarging milk circle with its center at the site of stimulation. This milky wave is due to changes of intensity of the light scattered in the invaded tissue. These properties allow us to study the Leão’s wave with this retinal preparation (Oliveira-Castro & Martins-Ferreira, 1977).

Under defined physical and chemical conditions, an experimental baseline “state” of the retina was chosen as reference, in which the velocity of propagation of SD, after a mechanical or chemical stimuli, was shown to be  $3.7 \pm 0.2$  mm/min, at 300. Near this value, the velocity of propagation is a function of appropriately balance between physical and chemical factors in such a way that the spreading rate can be controlled by well-poised interplay of the components of the standard solution (Ringer), temperature, chemical factors and some drugs like the AEDs used in this work.

For the propagation study in his “in vitro” isolated retina, Martins-Ferreira and cols., (1974) developed a preparation in which SD keeps up circulating, arrested in a retina ring, since some variables like temperature and the superfusion flow are controlled. The phenomenon also keeps walking inside the circular track with uniform speed, during several hours. Where in the chemical composition of the Ringer basic solution used up for the superfusion had been established, with the method of “attempt and mistake”, for the exclusive purpose of obtaining the reaction in isolated retinas, at the work cited, the authors make a systematic study of the influence of each one of the solution components, in the propagation speed of the circulating wave of Leão,

study this that can be used, as well, for the non-circulation SD. Varying at a time the concentration of one of the components, inside a band that included the one used in the basic solution, we can evaluate the individual influence of each one of these components. We can see consequently, that is very clear the antagonistic action among ions potassium and magnesium, as well as an antagonistic relation among ions chloride and the propagation speed, inside the bands of explored concentration. It becomes clear, as well, the effect of the increase in the temperature, however there is a maximum (about 35°C) above of which the speed of the reaction starts to decrease. Martins-Ferreira and cols. (1970) opted, in this work, by the following composition for a Ringer standard (mM): NaCl 100, KCl- 6, CaCl<sup>2</sup> 1, MgSO<sub>4</sub> 1, NaH<sub>2</sub>PO<sub>4</sub> 1 and glucose 30. Finally was related the solution osmolarity influence, whose variation is inversely related to propagation speed of the SD. Using the Ringer's Solution standard to 270 mosmol and keeping itself the temperature around 30°C, the propagation speed of the SD belonged to 3,71+/- 0,21 mm/min. Keeping up these experimental terms, this speed is obtained routinely. We ask for the attention to the fact that this standard Ringer, experimentally developed, owns its peculiar electrochemistry balance that keeps up the isolated retina viable for many hours. Fig 1.




Fig 1: We can see the light scattered (spreading depression) after a mechanical stimulus in the chick' retina and the propagation of the Leão's wave in a sagittal cut of retina also after a mechanical stimulus.

## 1 | PHYSIOPATHOLOGY OF MIGRAINE

The vascular and neuronal theories could, therefore, be associated, if we consider the fact that the initial SD of the cortex, responsible for the focal neurological signals at the beginning of migraine crisis could depolarize some trigeminal sensitive fibers related to the pain sensation around of the pia-arachnoid blood vessels, on the level of the ganglion of Grasser and the ventral surface of the brain (Hardebo, 1991). This activation of the trigeminovascular system (TVS) would induce neurogenic inflammation, with increase of the vascular permeability, promoting vasodilatation and

swelling of the vascular wall (Moskowitz, 1984). At the same time, some inflammatory substances could be released from the sensitive fibers, for example: calcitonin gene-related peptide (CGRP), substance P (SP), and others cytokines as the alpha tumor necrosis factor (ATNF), leucotriens and some interferon's. Moreover, some local mastocytes would be activated. Other vasoactive neurotransmitters, like intestinal vasoactive peptide (IVP) and neuropeptide Y (NPY) could be released reflexively by some sympatic and parasympatic fibers, respectively. The orthodromic conduction of trigeminal pulses would carry on the pain perception. Some vasoactive peptides like neurokin A (NKA), somatostatin, IVP and dinorfin were already identified in afferent primary neurons. SP, CGRP and NKA were confirmed as neurotransmitters of the trigeminovascular system (Limmroty and cols. 1996). It was demonstrated that the cortical SD provokes the protoncogen expression "c-fos" in the cortex (Herrera, and cols., 1993) and in the trigeminal nucleus (Moskowitz and cols., 1993), suggesting a connection between Lion's wave and the activation of the TVS. This "protoncogen", a nonspecific marker of the neural activity, is well characterized as marker of cellular activation after harmful stimulus and expresses him at the level of the cytoarquitectural blade I and II, which wisely contains primary nonmielinized terminations (Limmroth and cols., 1996). Finally, it is considered that this cascade of events', specifically TVS's activation comes to provoke an arterial extracranial vasodilatation and an intracranial modification of the arteriolar vascularization, mostly in the pia-arachinoid circulation level, that could explain the vascular alterations observed during migraine attacks (Moskowitz and cols., 1993; Moskowitz, 1993).

SD in humans and the Lion's phenomenon relation with the migraine aura.

About 20% of the patients with migraine present visual manifestations that precede the pain crises (Ropper, 2005), the visual manifestations are characterized by scintillations that are propagated slowly by the patient's visual field (fortification spectrums) that are followed by a scotoma. Lashley (1941) analyzed the progression of its own visual aura, that consisted of a scotoma with a scintillate edge, that propagated slowly by his visual field. He proposed that scotoma resulted from a region with depressed neuronal activity in the cerebral cortex, and the scintillations were the resultant of a region with intense neuronal activity in the periphery of this depressed region. This phenomenon would be propagated in the cerebral cortex, according to their calculations, in a speed of 3 mm.min<sup>-1</sup> (Lashley, 1941). Lashley's hypothesis obtained an "experimental" support in 1956, when Grafstein demonstrated in the cerebral cortex of rabbits, that the wave front of the SD, was marked by a discharge of high frequency potentials, while in the cortical region affected by the SD, the neuronal activity were decreased (Grafstein, 1956).

The visual aura is the most frequent type of aura, and it has its origin in the

primary visual cortex (area 17), who is the cortex region with the biggest neurons density. Leão and Morrison (1945) were the first to suggest that the SD might explain the scintillate scotomas of migraine aura. Milner (1959) observed the likeness between the propagation speed of the SD in the rabbit cortex (3 mm.min<sup>-1</sup>) and the velocity of progression of the scintillate scotomas described by Lashley (1940) in their migraine own crises.

Migraine crises are accompanied by a marked reduction of the cerebral blood flow (CBF) initially in the occipital polar region, with propagation for the previous regions of the brain in a speed of 3 mm/min. These CBF's Alterations were already measured in patients with a migraine crisis, using a positron emission tomography (Woods and cols, 1994). The maxim reduction of the CBF is about 30-40%, very smaller than the CBF reduction necessary to carry on an ischaemia of the cerebral cortex (Pietrobon & Striessnig, 2003). This fact suggests that the visual manifestations of the aura are secondary of a cerebral cortical ischaemia of the cerebral cortex.

AEDs utilized in migraine prophylaxis.

Migraine is one of the commoner forms of headache. Between 6 to 8% of men and 12 to 14 % and of women suffer from migraine (Lipton and cols., 2002; Rasmussen and cols., 1991; Sher and cols., 1998; Silberstein, 1996). The prevalence during life in women and men is greater than 25%; before the puberty this is between 4 and 5 %. The peak of incidence of migraine attacks occurs between 35 and 45 years of life. In this phase the women are affected three times more than the men (Olsen 2004). As a fact, the frequents attacks of migraine carries an important alteration in the patients quality of life. As a consequence of this fact the World Health Organization (WHO) defined migraine as one of the 20 life limitation larger causes (disability) in the world (Maytal and cols., 1997). Migraine prophylaxis main goal is the reduction of its frequency, severity, duration of the "attacks" and the prevention concerning the use of high doses of abortive drugs. Migraine prophylaxis is considered effective in case of reduction in at last 50% of the frequency of the "attacks" (Diener, 2007).

A recent study with the use of mice as an experimental model suggests that the cortical SD is a therapeutic target for migraine prophylaxis with the use of AEDs (Ayata and cols., 2006). In this study mice were cared for some weeks (on an average of three), with AEDs (Topiramate, Divalproate semisodium and Gabapentin). The treatment impact is measured through the events frequency of SVV provoked with the use of chemical stimulus (KCl-) or mechanical stimulus. The continuous use of AEDs suppressed SDs' frequency provoked in 40 to 80 %.

Divalproate of Sodium (DV) is made up of Valproate of Sodium and Acid Valproic acid in a molar reason of 1:1. The ion Valproate is the acid circulation form Valproic acid in the blood. DV has several action mechanisms in the Central Nervous System (CNS), who include the acid synthesis increase  $\delta$ -amino butyric acid (GABA) and



the reduction of the degradation of GABA, because it inhibits the enzyme GABA transaminase (GABA-T) that degrades the GABA. Beyond of these effects, the drug also blocks voltage dependent Na<sup>+</sup> channels and increases the conductance of channels of K<sup>+</sup> / Ca<sup>2+</sup> dependent (Cutrer and cols., 1997). Their main side effects are weight gain, mostly at the beginning of the treatment besides hiperamonmia and moderated alterations of the tests of renal function. (Victor & Ropper, 2005)

Gabapentin (GP) (Acid 1-amino-metilciclohexanoacético) is a new aminoacid created from the addition of a radical ciclohexano to the structure of the GABA. Gabapentin in concentrations of 100 μM interacts with the α<sub>2</sub>β subunit of the Ca<sup>2+</sup> channels type T, reducing the current for these channels (Rogawski & Löscher, 2004). Gabapentin also increases the concentration of GABA in the brain (Yacubian, 1998). Can be associate to leucopenia and anemia (Victor & Ropper, 2005).

Topiramate is a derivate sulfanate-substituted of the natural monosaccharide D-fructose. It owns multiple mechanisms of action, that include blockade of Na<sup>+</sup> channels, voltage-dependents, potencialization of the GABA<sub>A</sub> current mediated by an action in a different location from benzodiazepinc action site, block of glutamaergic receptors AMPA and blockade of Ca<sup>2+</sup> channels type L (White, 1997; White and cols., 1997). Is associate to the glaucoma and hypercholesterolemia. (Victor & Ropper, 2005).

Lamotrigine (LT) besides inhibiting voltage-dependent Na<sup>+</sup> channels stabilizes the neuronal membranes and acts as a pre-synaptic modulator for the release of excitatory aminoacids (glutamate) and inhibitory (GABA) (Wang and cols., 1996; Steiner and cols., 1997). The main limitation for the clinical use of this drug is a cutaneous rash in about 1% of the patients; rare cases of reversible chorea have been reported (Victor & Ropper, 2005).

Levetiracetan (LV), besides the partial inhibition of the Ca<sup>2+</sup> type N channels, acts in the opposition activity of some negative GABAergic modulators. It seems that the site of ligation of the drug is the synaptic protein SV2A. Through of this connection the drug modulates the release of some excitatory neurotransmitters and promote a facilitation of the GABAergic effect (Lynch and cols., 2004). It is associate to sleepiness and vertigos (Victor & Ropper, 2005).

## 2 | OBJECTIVES

1. Verify the effect of these drugs at tissue “in vivo”;
2. Based on clinical observation that the five drugs in study are effective in migraine treatment with and without aura and, as well, in the epilepsy, verify the GABAergic transmission involvement in the SD. Like a parameter of GABAergic activity, it will be measured the GABA-t activity “in vitro”, in isolated retinas of

chick (Gallus gallus) submitted by a mechanical stimulus to the Lion's phenomenon (SD), isolated and in the presence of the main drugs in study;

3. Determine the minimum, maximum and average dose of the drugs in study, without producing irreversible lesions, also enabling relative power verification of these drugs at tissue in this experimental model;

4. Verify the effects of Gabapentin, Valproate semisodium, Topiramate, Lamotrigine and Levetiracetan in the following parameters:

- Speed propagation;
- SVV's amplitude;
- Deflagration threshold;
- Absolute refractory period.

### 3 | MATERIALS & METHODS

#### 3.1 Animals

In this work were used chicks' Gallus gallus domesticus (White Leghorn) females and males, with age between 10 to 20 days, age considered ideal for the study of their retinas.

#### 3.2 Prepare of the retina fragments and solutions

The animals, with age of 10-20 day and weight of 50-90 g. were sacrificed by beheading, enucleated and the eyeball sectioned in its equatorial region to remove the vitreous humor. Soon after, the posterior hubcap was sectioned in rectangular fragments of 0,5 x 3,0 cm, and the retina is separated of the others ocular layers with a dissection tweezers.

Each animal was used to a unique experience.

The retina was put in Petri's Plate contend Ringer's reference solution (Rref), with the following composition (in mM): NaCl 100; KCl- 3; MgSO<sub>4</sub> 1; NaHCO<sub>3</sub> 30; NaH<sub>2</sub>PO<sub>4</sub> 1; CaCl<sub>2</sub> 1; Glucose 15. In this work, this Ringer's Composition was defined as ideal after several pilots' experiments (about 30) done with and without some drugs in study, whose goal went to the obtainment of a Ringer composition effective for the study in other words, with a susceptibility average for elicitation of the phenomenon. The tissue was put on a paper of percolate black and carried to a chamber of acrylic, with close volume of 0,2 ml, in one circuit with total volume of 4.0 ml, which was superfunded with Rref to a flow of 1,0-1,8 ml.min<sup>-1</sup> using a Harvard peristaltic bomb. The temperature was kept in 30-31°C, and the Rref saturated, along all the experience, with carbogenic (95% O<sub>2</sub>- 5% CO<sub>2</sub>), the pH kept in 7.4-7.6.

The model was used not only for visual inspection of the variations of spread

light (light-scattering), as for the voltage slow variation record, deflagration absolute refractory period and deflagration threshold. The superfusion chamber was made starting from a block of acrylic, having in the superior compartment a hemispheric or rectangular receptacle, to accommodate respectively a fragment of retina or the posterior hubcap of the eyeball in study. That compartment was bathed by Ringer's Solution standard (Rs), led through a polystyrene tube and impelled by means of an infusion bomb (Harvard Apparatus CO.), by a constant flow of 1.2 ml/min.

That polystyrene tube, when entering in the chamber, is coiled about himself and accommodated in a compartment at the bottom, before of being addressed to the retina location in study. That inferior compartment was endowed of a flow of heated water, supplied by a thermostatic bath (Form Scientific Inc.), what came to enable the solution heating of Ringer standard during his course by the reeled of the polystyrene tube, before reach the retina compartment, where the temperature was kept to 30°C, in bath adjustment function. The solution conductive polystyrene tube of Ringer standard was intercepted, between infusion bomb and the chamber, for a system of valves through which was possible to introduce the solution test (drugs in study) in Ringer's Chain. In the superfusion solution exit were positioned the electrodes of record.




Fig 2) Superfusion chamber outline where will be kept the retina fragment. The numbers 1 and 2 represent both local used to stimulate the tissue. W- bath water; R- solution of Ringer; P1 and P2- Electrodes of record put about the "retina confetti".

### 3.3 Microelectrodes

They will be used microelectrodes of glass (capillary with filament, 1,5 x 0,86 mm, Systems, Inc.) with external diameter of tip between 1 and 3 mm, stretched in puller

NARISHIGE (MOD. PE-2) and filled out by a solution of NaCl's 150 mM. The tip of the microelectrode will be observed by the dissection microscope until touch the vitreous surface of the retina. The glass tubes were filled out through its non-capillary extremity, with the help of a sharp glass tube, with tip diameter around  $70\mu\text{m}$ , connected to a syringe. Finally, both microelectrode tubes received each one of them, an Ag+/AgCl thread. These threads were linked to the entrance of an electrometer of two channels (Electromiter model FD 223 World Precision Instruments), whose exit was connected to a differential amplifier. The quality of amplification of the system was tried through pulses of electric chain, generated by a battery put in the circuit, in series. The checked values were registered in a polygraph Grass, model 5D (Grass Instrument CO., It uses).

With the help of a micromanipulator (Narishige Scientific Instrument Lab. Japan) the microelectrode tip was put in the internal plexiform layer of the retina, in other words, in the location where were verified the biggest manifestation of the Lion phenomenon. Thus was possible to check the voltage variation during the reaction.

The experimental montage was provided by a reference electrode, landed, with Ag+/AgCl<sub>2</sub>, whose metallic thread was inserted in the light of a glass tube performed with Agar, in solution of NaNO<sub>3</sub> 1 M. The inferior extremity of this tube was obstructed by a small disk of porous pottery, propitiating contact with the superfusion solution, in the point in which she was being drained of the chamber. (Fig.2)




Fig.3) Preparation outline of isolated retina: Plexiglas chamber. 1 and 2: record electrodes. 3: indifferent electrode. 4: Superfusion bomb. 5: Tungsten probe.

### 3.4 Drugs in study

At present work were used the next AEDs: DV, GP, TP, LV and LT. The Semisodium Divalproate used were the one of presentation in capsules of 125mg. The content of the same will be dissolved in Rs. and the resultant solution percolated in a "Millipore filter". Was used concentrations between 0, 07 and 7 mM, having as reference to concentration of 0, 7 mM, which is the therapeutic concentration of



the drug in human beings serum (Yasui-Furukori and cols, 2007; Nikitina and cols, 2006; Pucci and cols, 2003). Gabapentin is commercialized in capsules of 300 mg, whose content was dissolved in Rs. and afterwards filtrate. Was used concentrations situated between 6 and 600  $\mu\text{M}$ , once the therapeutic concentration of this drug in the human plasma it situates around 60  $\mu\text{M}$ . (Joetta and cols, 2003; Belal and cols, 2002; Ratnaraj and cols, 1998). Topiramate was used in the form of 25 mg capsules. The capsules was macerated and solubilized in Rs., and the percolated resultant solution was used in a concentrations situated between 3 and 300  $\mu\text{M}$ , once Topiramate therapeutic concentration in the human plasma it situates next of 30  $\mu\text{M}$ . (Bahrami & Mahammadi, 2007; Johannessen & Tomson, 2006). Lamotrigine was, as well, used in the form of 25 mg capsules; it was macerated and solubilized in Rs. for posterior filtration. Was used concentrations situated between 1 and 500  $\mu\text{M}$ , once Lamotrigine therapeutic concentration in the human plasma it situates near to 20  $\mu\text{M}$  (Lampl and cols., 2005). Finally, Levetiracetan was used in the form of capsules of 500mg that were macerated and solubilize in Rs. For posterior filtration it was used concentrations situated between 10 and 500  $\mu\text{M}$ , since the therapeutic concentration of the drug in the human plasma it situates near to 100  $\mu\text{M}$  (Coupez and cols., 2003; Patsalos and cols, 2000). We opt by the use of the available medication in the pharmaceutical market, with the goal of approach the real terms available to the users in day by day. It was done, however, an effective research among laboratories that make the available drugs for the survey.

### 3.5 Lion wave deflagrations

It denominates spontaneous SD (SDexp.) to that which arises without the retina being submitted to any stimulus. In all experiences, except in cases where is accomplished the deflagration threshold measure of the SD (chemical stimulus), the reaction was elicited by means of “mechanical stimulation” of the retina using a tungsten thread with the tip affiliated in about 100 mM. The stimulated location presents, frequently, a puncture lesion, observed to the dissection microscope. The tissue lesion in the stimulated location checks to the type of stimulus a character more structural than mechanic, characterizing him as an over threshold, fact that enables the measure of the absolute refractory period.

### 3.6 Voltage slow variation Records of the voltage slow variation (SVV) of the SD

It was used microelectrodes of glass (capillary with filament, 1,5 x 0,86 mm, Systems, Inc.) with external diameter of tip between 1 and 3 mm, stretched in puller NARISHIGE (MOD. PE-2) and performed with a solution of NaCl- 150 mM, as previous description. Microelectrode tip was observed to the dissection microscope

until touch the vitreous surface of the retina. Microelectrode tip position is given by the amplitude comparison between the amplitude and the form of SVV obtained with previous records (Martins-Ferreira and Do Carmo, 1987) where was made histological demarcation, serving of criteria for the tip location in the internal plexiform. The reading in the scale of a personal computer NARISHIGE manipulator, as the microelectrode tip penetrates inside the woven, serves of additional criterion for the tip location, situating itself between 70 and 120 mm from the point in which electrode touched the vitreous surface of the retina. Electrodes were linked to a WPI (FD 223) electrometer with entrance high impedance (1013 Ohm) and SVV registered in a polygraph Grass (mod.79) with two channels. After the positioning of the electrodes in the internal plexiform layer, the retina remained in the chamber for a period of 15 min. without being submitted for mechanical stimulus, before start SVV's Measures, speed of the SD, absolute refractory period and threshold.(Fig.3)

### **3.7 Measurement of the propagation speed of the SD**

In the experiences, the reaction was evoked in a retina region near the exit location proximities of the Ringer superfusion chamber. The reaction speed was calculated measuring time expense for the SD to running through the distance (4-5 mm) between two microelectrodes of glass (1-5 micromeres), positioned in the internal plexiform layer of the retina and aligned orthogonally ahead of wave front. Each microelectrode was connected to an electrometer (WPI). It denominates SD propagated (SDprop.) To the SD that, evoked by mechanical stimulus, running through all the distance between both microelectrodes, being detected by each one of the two microelectrodes in sequence (illustration). The speed was measure in retinas superfunded for Rref (control) and in retinas superfunded for 15 min. with Ringer's Solution contend different physiologic concentrations of each one of the five drugs: DV, GP, TP, LV and LT. The mechanical stimulus (prick) was done with the use of a Tungsten filament (100 tip diameter micrometers) in the period of time of 15 minutes.




Fig.4) Voltage slow variation representative tracing (SVV) registered by two successive electrodes. The propagation speed of the SD is estimate from the distance among records in the two channels, knowing the paper displacement speed that is constant during the whole experiment. Speed calculation of the SD (propagation): Space running through the paper by the SD under drugs action divided by 25 mm/min (paper speed); after, the value of the average distance between both electrodes is divided by the value found after the first operation. One retina "confetti" (biconvex cut of retina) is used.

In each retina preparation was verified the effect of a certain drug concentration in study. After a short period of balance in the Ringer's Solution, it was elicited SD with mechanical stimulus and, to follow, introduced into the superfusion circuit, a determined substance concentration of one drug in study. From three to four SD was, so, elicited with interval between these of 15 minutes and its corresponding speeds and amplitudes was registered. Next to the final, the retina is superfused with a Ringer's Solution without the drug (Rbi), one SD of control was obtained (DAref.).




Fig.5) Methodology for the evaluation of the reduction propagation speed effect of the SD in isolated retinas of chick. After the obtainment of two successive SDs with speeds of propagation constant (SD<sub>i</sub>). The substance, in the concentration to be studied, is added. Three successive SDs are afterwards obtained. The corresponding speeds are registered (V<sub>1</sub>, V<sub>2</sub> and V<sub>3</sub>, respectively). After wash with the solution standard (RBI.), one SD to be a final control is obtained. Mechanical stimulation is made by the use of a tungsten thread with tip sharpened to the about 100 micromeres, every 15 minutes.

Measured of the absolute refractory period ( $\Gamma_r$ ).

Starting from a first mechanical stimulus that results in one SD propagated (effective stimulus), several stimulus were applied in sequence, with time's intervals of 30 seg. between each stimulus, until a new SD propagated was obtained. With this procedure, it is measured the minor interval of time possible between a pair of SDs propagated ( $\Gamma_r$ ) evoked by the mechanical stimulus. Time was measured with a chronometer, that was activated when is applied the first stimulus that results in one SD propagated in the retina. Besides the  $\Gamma_r$ , also were measured the speed of the first and the speed of the second SD (V<sub>1</sub> and V<sub>2</sub>, respectively) and the voltage slow variation amplitude of the first and of the second SD (SVV<sub>1</sub> and SVV<sub>2</sub>, respectively). In the experiences in which it was used this protocol, the mechanical stimulus was applied in a region of the retina near to Ringer's entrance in the chamber, the SD is propagated in the direction of the Ringer's Flow.

### 3.8 Measured of the deflagration threshold of the SD

The deflagration threshold of the SD was measured using a protocol in which Ringer's solutions contend different concentrations of K<sup>+</sup> (starting from 8 mM) will be applied in the retina surface using a micropipette connected to an eject bomb. The location where was applied Ringer's solution with K<sup>+</sup> situates near the superfusion chamber exit. The ejection flow was situated in the interval between 20-200  $\mu\text{l}/\text{min}$ . and it was considered effective to the concentration of K<sup>+</sup> in the ejected solution that deflagrated the SD in up to 60 seconds (Martins-Ferreira and cols., 1993). The effect of DV, GP, TP, LT and LV on the deflagration threshold of the SD, for some solutions contend several concentrations of K<sup>+</sup>, was quantified by the use of different

concentrations of K<sup>+</sup> applied in retinas previously treated for 15 min with these AEDs.

Experiences with the administration of drugs “in vivo”.

The propagation speed of Lion's wave (SD), as well as the referred amplitude (SVV), was checked with the techniques used early (described early). In properly prepared retinas as described early. Five animals groups (Chicks' Gallus) with four elements in each was prepared; the animals age and weight was the same described before; three animals of each group were treated with ideal pharmacological dose for the species, equivalent to the physiologic average dose obtained in experiments made before. According to the group, the animals were treated with TP, GP, DV, LT and LV, for 15 consecutive days, using intraperitoneal applications. The forty of each group of animal, was considered as control and, consequently, was not treated. After 15 days the animals were sacrificed and their retinas prepared for the study of the SD parameters, as indicated previously.

### **3.9 Activity dosage of the GABA-T in control retinas and after multiple waves with and without the drugs in study**

Nowadays it is estimate that about 20 to 50% of the synapses of SNC, especially the located in the retina, use the GABA as your neurotransmitter, depending on the studied region (Young and Chu, 1990). The GABA is degraded by the GABA-T; enzyme that catalyzes the grouping amino transfer of the GABA for the acid  $\alpha$ -cetoglutaric, coming to supply intermediary metabolites for the cycle of acid tricarboxilic (Krebs) aiming the oxidative metabolism (shunt of the GABA). The GABA-T removes the GABA, converting it in the succinic-semi aldehyde through a transamination with  $\alpha$ -cetoglutarate, rebuilding glutamate molecule. Succinic semi-aldehyde is oxidized by NAD and by semi-aldehyde succinc dehydrogenase in NADH<sup>+</sup> and succinate that, then, comes in again to the Krebs' Cycle (Illustration). The GABA liberated in the synaptic rifts is entailed to the pre-synaptic stimulation of GABAergic neurons; its action about receivers target in the post-synaptic surface is finished with the reuptake of this by the nervous pre-synaptic terminals and by glia. This transportation that is mediated by the plasmalemma transportation system, besides being bi-directional is dependent to the temperature and to the extracellular ions Na<sup>+</sup> and Cl<sup>-</sup>. In ideal situations, the reason between GABA intracellular and extracellular is of about 200 times; in this way, the responsible force for this reuptake process is supplied by the movement of the Na<sup>+</sup> against your gradient (Martin & Olsen, 2000; Chen and cols., 2004). The reuptake GABA by the nervous terminations is then, reused or enters into the called “GABA shunt”, already described (Cooper and cols., 1991; Jung, 1978). The increased activity of the GABA-T in CNS, decreases the concentration of GABA carrying convulsive crisis, coma and death in mammals (Kang and cols., 2001; There be and cols., 1996); inversely, is expected that antiepileptic and /or antimigraine



drugs (AEDs) , come to increase the concentration of GABA. This fact might be the case of the drugs in study (TP, DV, LT GP and LV); their pharmacological actions may come to interfere and, maybe, decrease the activity of the GABA-T or come to block directly this enzyme, as the mechanism of action of Vigabatrine (Metacalf, 1979; Sherif & Orelan, 1995). To test the AEDs effectiveness in study , we check the activity of the GABA-T with a method based on kinetic analysis of the activity of the GABA-T with the use of spectrophotometry. (Nascimento and cols., 2007).

Chicks' with about 14 days of life, with close weight of 200 grams and free access the food and water, were separated in an specific place with temperature close of 25° C, and with normal light\dark regime. There was separated about 50 animals for this experimental phase.

The drugs and the equipment used in this phase were the next: I-Acid n-Gamma-Amino-Butyric-GABA (A-2129); II-Tetrazolium Nitro Blue "NBT" (N-6876); III-Nicotinamide Dinucleotide-NAD (N-0632); IV-Dimethyl Sulfoxide (D-8418),V-Acetic Acid (A-4508); VI-Tris (hydroxymethyl) amino-methane (T-1378) and VII- $\alpha$ -Cetoglutaric Acid (4210); obtained from the Sigma (St. Louis, MO, USA). Sulfuric Acid (Vitek) was given way by the laboratory of Neurobiology of IBCCF/UFRJ. It also was used an ultrasonic homogenized (HD2070, Bandelin, Berlim,); a refrigerated centrifuge (3K 30, Sigma, St. Louis, MO, USA), and a spectrophotometer (SPEKOL 1100, ZEISS).

The enzyme preparation was made with the own recipient used for the standard preparation used for the experiments described previously. Before the specific preparation, these retinas were submitted to the deflagration of a SD with mechanical stimulus, as already described protocol, without and with previous treatment for 15 minutes with three drugs in study (TP, GP and DV), in average dose already used in the previous phases also described, according to the animals group selected for control and for each drug. After this phase, the retina was "washed" with Ringer and the pigmented part of this retreat manually of the remaining. The retinas were then triturated with the use of an ultrasonic homogenater. The homogenate was centrifuged with a tampon solution of 4ml of Tris-HCl's to 50 mM (pH close of 8,4) for 1000g for 10 minutes to 4°C. The precipitated was then discarded and the overlie recentrifugated to 14000g for 20 minutes to 4°C. The "pellet" was treated again 4 ml of tampon (as already described) and used directly for the activity determination of the GABA-T.

The protein determination (protein dosage) of homogenate was determined according to Bradford's method (Bradford,1976).

The activity of the GABA-T is determined by the average incubation of 0,05 ml of 50mM of Tris-HCl (pH 8,4), 0.05 ml of substratum (contend it GABA, acid  $\alpha$ -cetoglutaric, NAD and NBT) and 0,1 ml of homogenate (0,1mg of protein). The

enzymatic reaction occurs for 20 minutes to 37°C. After this period the reaction is interrupted with 1,7 ml of sulfuric acid to 100mM. The reaction product is checked with the use of a spectrophotometer to 540nm.

Finally, we determine the curve that demonstrates the concentration effect of GABA and of the acid  $\alpha$ -cetoglutaric on the activity of the GABA-T, in function of the substratum. The reason between GABA and the acid  $\alpha$ -cetoglutaric was always kept in 1/0,7. The concentrations used of GABA went of 1mM, 10mM, 24mM and 97mM, respectively. Coordinated of the curves in: X-(S)mM (concentration of GABA ) and Y-H/PTN.-Mg/U(activity of the GABA-T). The concentration effect curve of protein in function of the activity of the GABA-T also was made, following the protein concentrations of 50, 100, 150 and 200  $\mu$ g. Coordinated of the curve in: X -  $\mu$ g PTN and Y - H/U.

The used enzymatic unit is arbitrary. "When we have the purified enzyme becomes easy to define itself as the enzymatic unit; when we have a tissue, the unit is defined as arbitrary unit. Therefore we have to dose the protein and normalize her for 1 hour, since the reaction occurs for 20 minutes." (Nascimento and cols,2007.).

The curve that demonstrates the concentration effect of the GABA and of the acid  $\alpha$ -cetoglutaric on the activity of the GABA-T in function of the substratum was made according to the following methodology: Average reaction contend 50mM of Tris-HCl (pH 8,4); 2,9 NAD's mM; 1,2mM of NBT diluted in 20  $\mu$ l of Dimethyl Sulfoxide (DMSO) and different concentrations of GABA and acid  $\alpha$ -cetoglutaric, namely - GABA (1, 10, 24 and 97 mM), acid  $\alpha$ -cetoglutaric (0,7, 7, 17 and 68mM). As already exposed, the reason between GABA and the acid  $\alpha$ -cetoglutaric was always kept in 1/0,7 in other words: For 1mM of GABA  $\rightarrow$  0,7 mM of acid  $\alpha$ -cetoglutaric was used. In the reactions in which the average doses were tried, the drugs in study, these drugs, in average effective doses, as already described previously, were added to the substratum.

The resultant curves were analyzed with the use of the program "GRAPHPAD PRISM" version 5.0. The statistical analysis was made, as well, with the help of GRAPHPAD PRISM version 5.0. It was used Kruskal-Wallis' Tests - one-way ANOVA - followed by the Dunn's Test's for multiple comparisons "versus" group control and the Friedman's Test, considering the controls values, in each experiment group, equal to 100% with the goal of the avoidance of variations of non-identifiable causes in the results bands of the different experiments.

## 4 | RESULTS

Determination of the speed and amplitude of the SD in mM/min and mV:

The results obtained can be analyzed with an objective form with the help of the

table below (table 1), where are represented the obtained data, in percentages, after analysis of all the experiments of this phase.

Table 1:

Drogas:	V(mm/min)	VLV (Mv)	Concentração Máxima
Levetiracetam	21,6%	11,6%	10 mM
Lamotrigina	41,2%	11,3%	1 mM
Divalproato	47,1%	23,7%	6 mM
Gabapentina	35,6%	28,4%	1.12 mM
Topiramato	67,9%	21,1%	600 mM

Table 1: Percentage of speed reduction in mm/min. and of the amplitude in mV of the slow variation of voltage, regarding the SDs initials. All of these concentrations variations are significant regarding the first stimulus (initials SDs).

The propagation speed variations of the SD, as well as of the amplitude of SVV, regarding the drugs used in the study can be visualized, with clearness, in the graphics below. During this phase of work phase were done, for parameter, four mechanical stimuli, with tungsten probe and with time's interval of 15 minute between these, initiating by the control, solution of Ringer "basic" (RB) and progressing, most of the time, for six phases, with the drugs concentration increasing progressively, according to the pharmacological concentrations of the drugs, already described previously. At the end of each sequence, the retina is "washed" with RB, obtaining a Ringer's Solution after wash (Rbi.), During this process, another four mechanical stimulus are done (Fig.); during this experiments phase, the speed and amplitude go inexorably up, but do not reach the standard observed initial before the drugs introduction. It is possible that, if the experiences could be prolonged by a period greater than 6 hours (average of time's used for each experiment) until, at least, 24 hours the parameters evaluated by drug can come to come back to the normality; This procedure showed, however, improper in function of the time's availability lack to the same and, as well, in function of the fact that the retinas kept in the preparation at issue tend to die after 12 utilization hours.

The doses used in the experiments were based on pharmacological doses used to the prophylactic treatment of migraine treatment.

Determination of the deflagration Threshold:

In this phase were checked, for every drug in study, the deflagration threshold measures regarding a chemical stimulus done with KCl-, in different concentrations, starting from 8 mM. The characteristics and concentrations of each drug, as well as the physical characteristics of the environment in study, are described before each experiments sequence. For each substance ten experiments were done. The deflagration threshold was checked, for drug; regarding the concentration of KCl- (mM) minimum that was effective in generate SD, for each drug in study. A

comparative graph was done to the final of this phase. The drugs concentration in study was obtained by the median of the pharmacological concentrations used in the phase II (determination of the speed and amplitude) with 50% of this concentration more than the average concentration. Ejection flow of KCl-: 100  $\mu$ l/min.


The analysis of the obtained data in this work phase, we can easily verify that Topiramate was the drug that determined a largest deflagration threshold for the phenomenon. It was necessary a chemical stimulus of 19mM of Kcl- for deflagrating the SD with the use of this drug. This data reinforces the fact described in before in this work.

Table 2: Comparison of the effects five drugs regarding the deflagration threshold for a chemical stimulus (Kcl-).

1- Levetiracetan	2,3 mM	11 mM/K <sup>+</sup>
2 - Lamotrigine	320 $\mu$ M	13 mM/K <sup>+</sup>
3 - Divalproate	3,5 mM	16 mM/K <sup>+</sup>
4 - Gabapentin	365 $\mu$ M	18 mM/K <sup>+</sup>
5 - Topiramate	350 $\mu$ M	19 mM/K <sup>+</sup>

Table 2: We verify that Topiramate was the drug in which the deflagration threshold of the SD was larger (larger concentration of K<sup>+</sup>). Levetiracetan was the drug in which the deflagration threshold of the SD was smaller (smaller concentration of K<sup>+</sup>)

Histogram revealing an effects comparison of the five drugs regarding the deflagration threshold for chemical stimulus (Kcl-).



Graphic 1: Histogram revealing the results described in the table 7.

Determination of the absolute refractory period ( $\Gamma$ ).

In this phase were checked, for every drug in study, the measures of the absolute refractory period (in units of time's) regarding a mechanical stimulus, done without any drug, after the use of each drug in study, in effective average concentration, already determined by the simple average of the concentrations of each drug determined in the Phase II of the study, after "wash" with Rbi. The characteristics and concentrations of each drug in study, as well as the physical characteristics of the environment in study, are described before each sequence of experiences sequence. For each drug five experiments were done; after each one of these experiments, it was calculated the simple average regarding the data of each experiment. These comparative data, for drug, were used as standard for comparison. A comparative graphic was done in the final of this phase.

By the analysis of the data obtained work phase, we can easily also verify that Topiramate was to the drug that determined the largest absolute refractory period for the phenomenon. It was verified an absolute refractory period of five minutes and thirty-seven seconds for the deflagration of SD with the use of this drug. This data reinforces the observations of the phase II and III of this work.


Table 3: Comparison between the effects five drugs regarding the absolute refractory period for a mechanical stimulus.

1 - Levetiracetan	0:03:26
2 - Lamotrigine	0:03:07
3 - Divalproate	0:04:26
4 - Gabapentin	0:04:21
5 - Topiramate	0:05:37

Table 3: Comparative - Absolute refractory period, we verify that Topiramate was the drug in which the absolute refractory period was larger (0:05:37) and Lamotrigine was the drug in which absolute refractory period was smaller (0:03:07).

Graphic 2: Histogram revealing the comparison of the effects of the five drugs regarding the absolute refractory period for mechanical stimulus.





Graphic 2: Histogram showing the results described in the table13.

Experiences “in vivo”.

In this phase were checked, for each drug in study, the speed measures (mm/min) and of the slow variation of voltage (mV) in chick´ retinas, with average age of 15 days treated “in vivo”, for fifteen days with TP, GP, DV, LT or LV in effective average concentration and average dose adequate to the middleweight of each animal, with the use of intraperitoneal injections use daily. The animals remained in environment closed under heating for lamps of 60 watts, After 15 days the animals were sacrificed by beheading and the retina fragments superfunded with Rbref.. Mechanical stimulus were done every 15 minutes, For each drug were studied 4 animals, and 1 between these was considered control, not receiving, consequently the “treatment” with the drugs in study, After all the experiments, was calculated the simple average regarding the speed (mm/min.) and the voltage of the SVV amplitude (mV), These comparative data, for drug, were used as standard for comparison, two comparative graphs were done, in the final of this phase.

Of the analysis of the obtained data in this work phase, we can verify that all the studied drugs, in pharmacological concentrations corrected for weight and corporal mass of the animals treaties, did not provoke side effects and/or relevant toxicity that has carried to the death of some animal. All the drugs indeed crossed the hamate-retina barrier and probably also the barrier hamate-encephalic barrier. Topiramate was considered as well, in this work phase, the most effective drug and Levetiracetan the least effective regarding the studied drugs. This data reinforces the observations of the phase II, III and IV of this work.


Table 4: Effects comparison of the 5 drugs regarding propagation speed in mm/min and the amplitude in mV. “in vivo”.

	V(mm/min)	VLV (mV)
1 - Levetiracetan (2,3 mM,)	4,7	19,4
2 - Lamotrigine (320 $\mu$ M)	4,3	18,6
3 - Divalproate (3,5 mM,)	4,1	18,0
4 - Gabapentin (365 $\mu$ M)	4,6	17,4
5 - Topiramate (350 $\mu$ M)	3,0	18,1

Table 4: We verify that Topiramate was the drug in which speed was smaller (larger effect about this variable), Gabapentin was the drug in which the amplitude was smaller and Levetiracetan was the drug in which not only the speed but also the amplitude were larger (smaller effect about these variable). These important results are similar to obtained in the Phase II of this work.

#### Dosage of the GABA-T activity

With the use of three drugs in study: Topiramate, Gabapentin and Divalproate, besides control without the drug use, the band of used protein was, rigorously, inside the linearity. Six experiments in this phase were done. The doses of the used drugs in this phase corresponded rigorously to the effective average dose observed before in this work, in other words, 350 $\mu$ M of Topiramate, 365 $\mu$ M of Gabapentin and 3,5 mM of Divalproate. We could note that, after the data analysis obtained in the six experiments done with the drugs used, there is a clear tendency for the enzyme activity decrease. This fact suggests that, somehow these drugs act or directly or indirectly about the activity of this enzyme. This fact was proved, in this study, by the made statistical analysis of this work phase, where they were obtained statistically important results with the use of the proposed statistical tests (Kruskal-Wallis - one-way ANOVA - followed by the Dunn's Test for multiple comparisons “versus” group control and Friedman's Test).



**Atividade da GABA- T (Curvas Comparativos)**

	Controle		Topiramato		Divalproato		Gabapentina	
	Média	DP +/-	Média	DP +/-	Média	DP +/-	Média	DP +/-
1	6,02	0,63	5,29	0,6	4,77	0,52	5,13	0,52
10	5,97	0,57	5,03	0,63	4,54	0,61	4,84	0,56
24	5,6	0,52	4,82	0,58	4,49	0,59	4,7	0,56
97	4,24	0,56	3,63	0,54	3,65	0,53	3,6	0,52

Graphic 3: Dosage of GABA-T with three drugs in study ( Topiramate , Divalproate and Gabapentin ). Comparative curves.


Activity statistical data analysis of GABA-T:

Were used Kruskal-Wallis' Tests - one-way ANOVA - followed by the Dunn's Test for multiple comparisons “versus” group control and Friedman's Test. Due to cause variations not identified in the results bands in some experiments was made a transformation considering the values controls for each data sequence, inside the same concentration of GABA, used to the obtainment of the specific activity of the GABA-T, in each experiment group, equal to 100%.

Data analysis for all concentrations of GABA (1 , 10 , 24 and 97 mMs.) :

- able with data in perceptual, 100% - control.

## Gráfico de Distribuição



Graph 4: Dosage of the activity of GABA-T with three drugs in study (Topiramate, Divalproate and Gabapentin). Distribution graph for all studied concentrations of GABA.

### Kruskal-Wallis' Test:

$P < 0,0001$ , gaussian approach. ( $P < 0,05$ ).

Multiple comparative test of Dunn's:

CTRL X TO: 38,75 ( $P < 0,05$ ).

CTRL X DV: 48,58 ( $P < 0,05$ ).

CTRL X GP: 44,67 ( $P < 0,05$ ).

### Friedman's Test:

$P < 0,0001$ , gaussian approach. ( $P < 0,05$ ).

CTRL X TO: 37,00 ( $P < 0,05$ ).

CTRL X DV: 50,00 ( $P < 0,05$ ).

CTRL X GP: 45,00 ( $P < 0,05$ ).

## 5 | DISCUSSION

This work suggests that basically, in this model and clinically effective concentrations, antiepileptic drugs preferably with a modulator of GABAergic mechanism of action phenomena (MGF) (Wiedemann et al, 1996; Calabresi et al, 2007), which have been used for the chronic treatment of migraine, may interfere with the Lion phenomenon, concentration-dependent manner. This interference can lead to a decrease not only the speed of propagation of AD (in mm / min) but also its amplitude (in mV), triggering threshold and absolute refractory period.

Migraine is a multifactorial inherited disorder in the brain involves a dysfunction of subcortical structures that modulate the afferent sensory stimulation. Currently, migraine is explained not only by a vascular mechanism but also by a heterogenic channelopathy related to some ions, resulting in the phenomenon of spreading

depression. The development of drugs that may provide a reduction in cortical hypersensitivity states (action on ion channels) seems like a good way for the prophylactic treatment and for acute migraine. Based on this point of view, the use of GABAergic drugs has been approved for the prophylactic treatment of migraine from 2003. (Puppe & Limmroth, 2007).

The mechanism of action of drugs that act in the prevention of migraine are many, but it is postulated that these will converge on two targets: inhibition of cortical excitation and control of nociceptive demodulation. It seems that the lack of proper modulation of GABAergic inhibition system in some areas of the brain have to have a key role in the pathogenesis of the disease (Calabresi et al, 2007). Antiepileptic drugs FGM, mainly topiramate, divalproex, gabapentin, levetiracetam and lamotrigine, which act as a Lion Wave inhibitors, are clear examples of drugs that reduce the cortical hyperexcitabilidade. Furthermore, modulators of the cholinergic and serotonergic appear to have also a role for the prevention of migraine since it can restore the nociceptive descending inhibition (Ramadan, 2007).

A number of experimental works by using in vivo models show the effectiveness of FGM drugs for inhibition of spreading depression and migraine prophylaxis consequent (Sanchez-Del-Rio et al, 2006, Akerman & Goadsby 2005). According to Ayata et al. (2006), chronic daily administration of these drugs, dose-dependent decreases the frequency of cortical of 40 to 80%, and increase the stimulation threshold for obtaining them. This work demonstrates, above all, that the model developed by Martins-Ferreira et al, FGM blocking drugs can come concentration-dependent way, even an avascular structure.

By virtue of the connection between a putative DA and migraine (Lion, 1944). Previous studies used the model of isolated retinal paint under the effect of a classic anti epileptic drug - diphenylhydantoin (HFD) - Chebabo & Do Carmo, 1991 on spreading depression induced by mechanical stimulation and / or químico. Observou up, in the study, the DFH not only increases the KCL concentration threshold for the outbreak of the phenomenon as also decreases the speed of propagation of AD. It was not done, however, a "link" between the observed and the prophylaxis of migraine, perhaps by the fact that, to date, we do not know the correct the DFH mechanism of action. In fact, the literature makes no reference to the prophylactic use of DAP in migraine, although several drugs used in this prophylaxis are anti epileptics.

Martins-Ferreira and Ribeiro effected preliminary experiments topical application in the cerebral cortex of rabbits (1 mM) and injection (6 mM) of Sumatriptan, a drug used clinically as "abortion" in acute migraine phase. With this method did neither blocking nor reducing the speed of VLV. However, blockade of DA was obtained Sumatriptan, serotonin and / or Ergotamine in the range of 0.5 - 5.0 mM, isolated chick retina (Maranhao-Son, 1997). Moreover, Wiedemann et al, 1996, obtained



similar results with Sumatriptan, but not with Ergotamine.

In 1993, Martins-Ferreira et al, and check the action of various channel blockers, compared the speed reduction caused by serotonin and by Sumatriptan. It was concluded that serotonin in 3 mM concentration caused a dramatic reduction in propagation speed of AD, followed by complete blockage of current DA, Sumatriptan while, at the same concentration, was more effective in blocking the DA 2 -5 min.

In 2005, Akerman and Goadsby, studied the effect of topiramate on the cortex in the cat and mouse and found that the drug, at a dose of 30 mg / kg, can inhibit DA 90% of the animals. Margineanu and Klitgaard, 2009, also studying rat cortex models, significant results obtained with regard to the inhibition of the use of Brivaracetam (UCB-34714), experimental drugs with high binding affinity for synaptic protein SV2A and close relative, but more powerful, of levetiracetam. This paper presents more complete results than those described above because, in that dosages were used "clinics" of FGM drugs used for the prophylactic treatment of migraine. In this event, the model used in the work (chick retinas) seems to be more reproducible than those seen studies that used the chick retina structure is avascular, been allowing the occurrence of a "neural effect - on neurons and / or glia - "drug under study.

Furthermore, all of our results with the drugs tested both in vitro models as in vivo models were effective; independent of this case leaving to consider the passage of the drug through the blood-brain barrier.

We observed initially, after completion of the Phase II study all drugs that interact in some way with the phenomenon described within the context of the proposed experimental (isolated chick retina). There is a decrease in different proportions from both the propagation velocity in mm / min. as the amplitude of AD mV after mechanical stimulus in all the preparations according to the proposed drug effect. This reinforces the concept of the GABAergic transmission, and is an important phenomenon for Spreading Depression (both generation and propagation) is central to the pathophysiology of migraine.

Initial experimental results appear to be in agreement with the reviewed medical literature (migraine prophylaxis). The drug, which according to experiments done in this work, presents the best result in the context of decreased DA velocity is topiramate (decrease of 67.9% in the rate of spread). This fact, in addition to being relevant, is in line with most of the work described in the medical literature.

Recently, topiramate was considered by the European Neurological Society the drug of choice, within the group of antiepileptic drugs for the prophylactic treatment of migraine. The second drug with better performance in this study is the Divalproex (decrease of 47.1% in the rate of spread), a fact that is also in line with the main studies reviewed. Today Divalproex is the second most used drug in Europe, within the group of antiepileptic drugs for the prophylaxis of migraine and the first option,

within this group, USA. Gabapentin was reduced by 35.6% in the rate of spread of DA; this fact reveals only a partial reasonable result for the drug in question. The literature review for Gabapentin reveals that this drug was considered at the end of the last decade, very promising for the prophylaxis of migraine. However, the main clinical studies at the time did not present encouraging results, a fact which, added to various side effects of the drug, was of relevance to the placement of this drug in the background, in the prevention of migraine with drug use antiepileptic.

In this experimental study, lamotrigine decreased by 41.2% in the rate of spread of AD. This fact, in addition to being consistent with the medical literature, is quite encouraging, given that we are dealing with a new drug. The Lamotrigine has been the focus of important clinical studies in the past five years, all with encouraging results. Several therapeutic approaches have emerged for the use of this drug in migraine prevention protocols in Europe; however, because it is a relatively new drug, new studies should be developed. In this experimental work, Levetiracetam fell by 21.6% in the speed of AD, a fact considered very encouraging and consistent with little medical literature. The Levetiracetam, drug walking newer than Lamotrigine, has been the target of some clinical studies isolated for migraine prophylaxis, due to its innovative mechanism of action, and its positive results in the context of control of complex epileptic frames. The results of these tests have been very encouraging, however, still make up needed more clinical studies (more significance level) for a complete evaluation of the potential of this drug for the prophylaxis of migraine. We draw attention, however, to the fact that the Brivaracetam (ucb-34714), more powerful experimental analogue that Levetiracetam, seems to have the best effect on the AD than the latter. (Margineanu and Klitgaard, 2009).

All drugs studied had, in varying proportions, a decrease in the amplitude of the DC. The drug with the highest percentage reduction in this variable mV was Gabapentin (28.4%). Topiramate. Despite having the largest percentage decrease in speed of propagation, showed only a reduction of 22.1% in the amplitude of DC. We believe it is important in the experimental context, verificarmos a decrease in the amplitude of DC when studying drugs that modulate the Lion phenomenon. However, further studies are needed in this area because they have not mastered in full, the biochemical and physiological phenomena involved in "phases" of the call Lion Wave.

Finally, we would like to emphasize that all results obtained in this phase of the study were reversible with time. In all experiments done after we get the maximum proposed dose for each drug, an increase in speed and amplitude of the DC when the retina (cutting) was again washed only with Ringer, after the removal of each drug in Bath study .

In phase III of this work, the firing threshold of in relation to a chemical stimulus done at high KCl concentrations, in mM, was measured based on the model proposed

by Martins-Ferreira (Ferreira-Martins et al., 1993). From the concentration of 8 mM, chemical stimulus was increased gradually until the measurement of the concentration limit for the firing of DA, for each drug in estudo. A analysis of the results obtained in this phase shows that the threshold of outbreak obtained with higher concentrations of KCl occurred with topiramate, with a concentration of 19 mM KCl. This fact is consistent with the results obtained so far and also to the journal literature. We can, directly, stating that among the five drugs under study, topiramate was shown to be the most potent in blocking or decrease the DA.

Gabapentin presented an outbreak threshold in 18 mM KCl, a fact that can also be considered effective seen that the drug in question has shown results in many experiments, however, has been in the background in relation to Topiramate and Divalproex. The Divalproex presented, in turn, one outbreak in 16 mM threshold, threshold that puts you at an intermediate position in relation to the drugs under study. The drug showed lower firing threshold was Levetiracetam, this drug has not shown encouraging results among the antiepileptic drugs for the prophylaxis of migraine. May be of relevance to the study of his most potent analog, Brivaracetam (ucb-34714).

We can only draw attention to the fact that, in this work phase, the concentrations of the drugs under study, used in the experiments represented the median of pharmacological concentrations studied in phase II as well, a concentration greater than 1.5 this median.

In phase IV study was measured absolute refractory period of study drug, in units of time, for an effective mechanical stimulus for triggering AD. At this stage, too, topiramate was found to be more potent compared to other drugs being studied. The absolute refractory period for Topiramate was 5 minutes and thirty seven seconds followed by obtained for Divalproex in 4 minutes and twenty-six seconds. The lower refractory period was measured Levetiracetam, in 3 minutes and twenty-six seconds. These results are in agreement with the literature reviewed and the findings of the phase II and III of this work.

In vivo experiments in which pharmacological concentrations of the drugs under study were used, ie the median of concentrations used in the experiments of Phase I was found that in all study drugs, changes, even if minimum, speed, and amplitude of the obtained retina of animals after the same treatment for 15 days and sacrifice by decapitation. Again, at this stage the drug showed that topiramate was most effective (measured speed of 3.0 mm / min and amplitude of VLV, measured to be 18.1 mV) followed by Divalproex (measured speed of 4.1mm / min and amplitude of VLV, measured 18 mV). The drug is the least effective was, again, the Levetiracetam (speed measured at 4.7 mm / min and amplitude of VLV, measured in 19.4mV). These findings are in strict accordance with literature findings and phases I, II and III of the

work in question. It is important to note that all drugs, at physiological concentrations, crossed the blood-brain barrier and have provided some effect on the DA, in animal studies; this fact is also seen according to the literature, all drugs studied seem, MGF by mechanisms and possibly other more or less effective in the prophylaxis of migraine. This fact does not seem to happen for Sumatriptan seen that, in an experiment similar to this work, Maranhão-Filho (1997) found that the required dose of this drug in effective concentration, so that it had some effect on the Lion Wave, should be in the order of 100 g / kg dose this extremely high and toxic for use in vivo.

In VI phase of this work we chose the dosage of GABA-T activity, following the birth protocol et al (2007), for measuring the activity of this enzyme. In this study, we used the chick retina without the use of these drugs and without mechanical stimulus to the elicitation of AD and chick retinas with three drugs studied (topiramate, gabapentin and Divalproex) and without the drugs under study (control), with DA elicitation by mechanical stimulation (tungsten pin). The point of this phase was to verify that GABA-T activity, protein concentrations within the linear range of the standard curve of protein in all six experiments, with the use of three drugs under study came to decrease, U / mg STP / h compared to control, significant  $P < 0.05$  - Kruskal-Wallis and Friedman -. However, in all experiments, the decline of the GABA-T activity was very small relative to that observed with the use of vigabatrin - anticonvulsant drug that works by blocking the GABA-T - (Graeme, 2003; Nascimento et al, 2007) . This suggests that inhibition of GABA-T, there seems to be neither the only nor the main mechanism through which the electro-physiological effects are manifested. Antiepileptic drug / antimigranosas that have been studied seem not act exclusively on the inhibition of GABA-T activity. Another aspect that we can only focus is the fact that the GABA-T seems to have a different mechanism of inactivation in the retina compared to that observed in the brain; This fact provides a "limited" increased GABA concentration in the retina compared to that observed in the brain (Rando et al, 1982).

In the cerebellum, the values of the enzymatic reaction of GABA transaminase in units are around 200 U / mgPTN / H (Nascimento et al, 2007). In the retina the values found in this study are about 5 to 6 U / mgPTN / M, or 30 to 40 times lower than that found in that organ. This difference could be related to retinal features, ie: if the expression is neuronal or glial, moves with the development, it is affected by the environment, especially by light, is affected by hormones and / or extracellular factors and is modulated by GABA itself.

The release of GABA and acetylcholine in AD is reproducible, as the voltage changes, potassium, chloride and water movement (Martins Oliveira-Ferreira and Castro, 1966; Nicholson and Kraig, 1981; Martins- Ferreira and Do Carmo, 1984 ). The reduction to 0.5 mM calcium and magnesium to increase 2.0-4.0 mM in

the extracellular medium decreases both the phenomenon of "light-scattering" as increasing the concentration of potassium and acetylcholine and GABA release during AD. This phenomenon suggests that at least in part, the mechanism of release of GABA and acetylcholine in AD, either from synaptic mechanisms. Despite this fact, it is not possible to be established whether the release of GABA and ACh are essential for the occurrence of the phenomenon or if it occurs concurrently with this (Rodrigues et al, 1988). It is known, however, that much GABA and anti-physiologic high concentrations (about 3.0 mM) can come to lock the retina in a short period of time (Rodrigues et al, 1988). In 1987, Roberts et al demonstrated that the use of eserine (cholinergic agonist) is able to decrease GABA release during AD. This suggests that the DA in different CNS regions, at least in part, there is a direct influence conjugates mechanisms between at least two neurotransmitters, particularly the retina (Rodrigues et al, 1987).

Finally, we draw attention to the fact that the main focus of this work was to study the spreading depression and the effect of GABAergic drugs used in migraine prophylaxis rises this, not the study of the effect of these compounds on the GABA-T kinetics. It is suggested for future experiments assessing the effect of these compounds vigabatrin more brivaracetam and, depending on the kinetics of this enzyme. On this occasion should be made "bows" over "spots" and with higher concentrations of the compounds, a fact that would be desirable in order to obtain a more reliable analysis of the kinetics of GABA-T. We believe that in the context of this paper, to obtain a correlation between the effect of compounds on enzyme kinetics, even if a trend is rich.

## 6 | CONCLUSIONS

1. antiepileptic drugs and / or antimigranosas with modulatory action on GABAergic transmission mechanism, that is, GABAergic drugs such as topiramate, gabapentin, divalproex, and lamotrigine Levetiracetam reversibly reduce the rate of AD in mm / min, and the amplitude of AD in mV in isolated chick retinas, subjected to mechanical stimulation, concentration-dependent manner.

2. topiramate, gabapentin, Divalproex, Lamotrigine and Levetiracetam increase reversibly both the ignition threshold for AD as the refractory period of AD, in units of time, in isolated retinas subjected chicks, respectively, to chemical stimuli with KCl in specific concentrations and mechanical stimuli, such concentration-dependent.

3. Topiramate is most effective drugs of which were studied, with regard to the reduction of velocity, amplitude increase in the absolute refractory period and triggering threshold of isolated chick retinas, reversibly and so the concentration-dependent.



4. Levetiracetam is less effective drug, of which were studied, with regard to the reduction of velocity, amplitude increase in the absolute refractory period and triggering threshold of isolated chick retinas, reversibly and so the concentration-dependent.

5. All the drugs studied (topiramate, gabapentin, Divalproex, Lamotrigine and Levetiracetam) appear in vivo cross the blood-brain barrier.

6. Topiramate is most effective in vivo drug of which have been studied in regard to deceleration.

7. Levetiracetam is less effective in vivo drug of which have been studied in regard to reducing the speed and amplitude of AD.

8. Both gabapentin and topiramate as divalproex decrease GABA-T enzyme activity in the experimental model under study, and possibly some modest important in functional terms, suggesting that inhibition of GABA-T is neither the one, or the main mechanism through which electro-physiological effects of the drugs studied were manifested.

9. The present study suggests that antiepileptic drugs that act on the GABAergic transmission, especially topiramate, may prevent migraine and interfere with the generation and propagation of spreading depression.

## REFERENCES

1. Akerman, S., Goadsby, P.J. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. *Neuroreport*. 16(12):1383-7, (22) 2005..
2. Avoli, M., Drapeau, C., Louvel, J., Pumain, R., Olivier, A., Villemure, J.G. Epileptiform activity induced by low extracellular magnesium in the human cortex maintained in vitro. *Ann. Neurol*. 30(4):589-596, 1991.
3. Ayata, C., Jin, H., Kudo, C., Dalkara, T. Suppression of cortical spreading depression in migraine prophylaxis. *Ann. Neurol*. 59(4):652-661, 2006.
4. Bahami, G., Mohammadi, B. A novel high sensitivity HPLC assay for topiramate, using 4-chloro-7-nitrobenzofurazan as pre-column fluorescence derivatizing agent. *J. Chromatogr. B. Analyt. Technol. Biomed. S.C.I.* 850 (1-2):400-4, 2007.
5. Belal, F., Abdine, H., Al-Majed, A., Khalil, N.Y. Spectrofluorimetric determination of Vigabatrin and Gabapentin in urine and dosage forms through derivation with fluorescamine. *J. Pharm. Biomed. Anal.* 27 (1-2):253-60, 2002.
6. Bradford, M.M., A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry*. 72:248-254, 1976.
7. Bures, J., Buresová, O. Weiss, T. Functional consequences of hippocampal spreading depression. *Physiol. Bohemoslov.* 9:219-227, 1960.
8. Bures, J., Krivanek, J. Ionic movements in the brain as studied with the AID of

washing the cortical surface with an epidural cannula. *PHysiol. Bohemoslov.*9:488-493, 1960.

9. Calabresi, P., Galletti, F., Rossi, C., Sarchielli, P., Cupini, L.M. Antiepileptic drugs in migraine; from clinical aspects to cellular mechanisms. *Trends. PHarmacol. Scienc.*28(4): 12-25, 2007.
10. Chebabo SR, Do Carmo RJ. Phenytoin and retinal spreading depression. *Brain Res.*1991 Jun 14; 551 (1-2):16-9.
11. Chen, N.H., Reich, M.E.A., Quick, M.W. Synaptic uptake and beyond: the sodium and chloride-dependent neurotransmitter transporter family SLC6. *Pflugers Arch. Eur.J.PHysiol.*447:519-531, 2004.
12. Cooper, J.R., Blom, F.E., Roth, R.H. Amino acid transmitters. **In: The Biochemical Basis of Neuropharmacology.** Oxford University Press, New York.133-89,1991,
13. Coupez, R., Staetemaus, R., Sehgal, G., Stocks, A., Zhihong, L. Levetiracetam; relative bioavailability and bioequivalence of 10% oral solution ( 750 mg) and 750 mg tablets. *J.clin. PHarmacol.* 43(12): 1370-6, 2003.
14. Cutrer, F.M., Limmroth, V., Mosckowitz, M.A. Possible mechanisms of valproate in migraine prophylaxis. *Cephalalgia.*17 (2):93-100, 1997.
15. Diener, H. Long – term effectiveness of Topiramate for migraine prevention: analyses of open-label extension-phase data from two pivotal studies, EFNS Congress, Athens. Poster P 2138, 2005.
16. Diener, H. Topiramate in Migraine Prevention. Seventeenth Meeting of the European Neurological Society – Rhodes/Greece – June 16-20, 2007. Pre-congress course.
17. Diener, H.C., Bussone, G., Van Oene, J.C., Lahaye, M., Schwalen, S., Goadsby, P.J. TOPMAT-MIG-201 (TOP-CHROME) Study Group, Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. *Cephalalgia.*27(7):814-23, 2007.
18. Do Carmo, R.J., Martins-Ferreira, H. Spreading depression of Leão probed with ion-selective microelectrodes in isolated chick retina. *An. Acad.Bras.Ci.* 56:402-421, 1984.
19. Gorji, A. Spreading Depression: a review of the clinical relevance. *Brain. Res. Rev.* 38: 31-60, 2001.
20. Gouras, P. Spreading depression of activity in amphibian retina. *Am.J.PHysiol.* 195:28-32, 1958.
21. Graeme, J.S., Butler, E., Forrest, G., Ratnaraj, N., Patsalos, P.N., Brodie, M.J. Vigabatrin, but not Gabapentin or Topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. *Epilepsia*, 44 (7):886-896, 2003.
22. Grafstein, B. Mechanism of spreading cortical depression. *J. Neurophysiol.*19:154-171, 1956.
23. Hardebo, J.E. Migraine – Why and how a cortical excitatory wave may initiate the aura and headache. *Headache* .31:213-221, 1991.

24. Hava, G., Adolfo, T.E., Drorit, S., Yoram, G. GABA metabolism controls inhibition efficacy in the mammalian CNS. *Neuroscience Letters*. 217:25-28,1996.
25. Joetta, M.J., Paul, I.B., Gwendolyn, A., Francis, M.U. Procedure for Monitoring of Gabapentin with 2, 4, 6-trinitrobenzene sulfonic acid derivatization followed by HPLC with ultraviolet detection. *Clinical Chemistry*.49:1198-1201, 2003.
26. Johannessen, S.I., Tomson, T. PHarmacokinetic Variability of newer antiepileptic drugs: When is monitoring needed? *Clin.PHarmacokinet*.45 (11):1061-75, 2006.
27. Jung ,M.J. In-vivo biochemistry of GABA transaminase inhibition. **In: Seiler N., Jung M.J., Kock-Wester J. (eds.) Enzyme-activated irreversible inhibitors.** Elsevier/North-Holland Biomedical Pres, New York. 135-48,1978.
28. Kang, T.C., Park, S.K., Bahn, J.H., Jeon, S.G., Jo, S.M., Choi, S.Y., Won, M.H. The alteration of gamma-aminobutyric acid-transaminase expression in the gerbil hippocampus induced by seizure. *Neurochem.Int*. 38:609-14, 2001.
29. Kraig, R.P., Nicholson,C. Extracellular ionic variations during spreading depression. *Neuroscience* 3:1045-1059, 1978.
30. Lampl, C. Z., Katsarava H., Diener, C., Limmroth, V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. *Journal of Neurology, Neurosurgery, and Psychiatry*. 76:1730-1732,2005.
31. Lauritzen, M. Cerebral blood flow in migraine and cortical spreading depression.*Acta. Neurol. Scand*.76:1-40, 1987.
32. Lauritzen, M. Cortical spreading depression as a putative migraine mechanism.*Trend. Neurosci*.10:447-467, 1987.
33. Leão, A.A.P. Spreading depression of activity in the cerebral cortex *J.Neurophysiol*. 7:359-390,1944a.
34. Leão, A.A.P. Pial circulation and spreading depression of activity in the cerebral cortex. *J.Neurophysiol*. 7:391-396, 1944b.
35. Leão, A.A.P. Further observations on the spreading depression of activity. *EEG. Clin. Neurophysiol*. 3:315-321, 1947.
36. Leão, A.A.P. On the inferred relationship of migraine and spreading depression. **In: Advances in headache research, (eds.) F. Clifford Rose. John Libbey&Co Ltd.** 19-24, 1987.
37. Leão, A.A.P., Morrison, R.W. Propagation of spreading cortical depression. *J.Neurophysiol*. 8:33-45, 1945.
38. Libet, B., Gerard, R.W. Control of the potential rhythm of the isolated frog brain. *J.Neurophysiol*. 2:158-169, 1939.
39. Limmroth, V., Cutrer, F. M., Moskowitz, M.A. Neurotransmitters and neuropeptides in headache. *Curr. Opin. Neurol*. 9:206-210, 1996.
40. Lipton,R., Scher, A., Kolodner, K. Migraine in the United States: epidemiology and

patterns of health care use. *Neurology*. 58(6): 885-894, 2002.

41. Lipton, R.B, Stewart W.F., Simon, D. Medical consultation for migraine: results from the American Migraine Study. *Headache*. 38(2):87-96, 1998.
42. Lynch, B.A., Lamberg, N., Noika, K., Kensel-Hammes, P., Bassalieh, S.M., Mategne, A., Fuks, B. The Synaptic Vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proc. Natl. Acad. Sci. -USA* – 101(26):9861-6, 2004.
43. Maranhão, F.P.A. Sumatriptan na Depressão Alastrante Retiniana. **Thesis**. 1997.
44. Margineanu, D.G., Klitgaard, H. Brivaracetam inhibit spreading depression in rat neocortical slices in vitro. *Seizure*. 2009, Feb 9. (Epub.)
45. Martins-Ferreira, H. Propagation of spreading depression in isolated retina. **In: Lehmenkühler, A; Grotemeyer, K.H. e Tegtmeier, F. (Eds.). Migraine: Basic Mechanisms and Treatment.** Urban & Schwarzenberg, München-Wien-Baltimore: 533-546, 1993.
46. Martins-Ferreira, H. Spreading depression: a neurohumoral reaction. *Braz.J.Med.Biol. Res.* 27:851-863, 1994.
47. Martins-Ferreira, H. Depressão alastrante na retina. *An. Acad.Bras.Ci.* 34: XLIV, 1962.
48. Martins-Ferreira, H., Do Carmo, R.J. Retinal spreading depression and the extracellular milieu. *Can.J.PHysiol.PHarmacol.* 65:1092-1098, 1987.
49. Martins-Ferreira, H., Oliveira-Castro, G., Struchiner, C.J., Rodrigues, P.S. circling spreading depression in isolated chick retina. *J.Neurophysiol.* 37:773-784, 1974.
50. Martins-Ferreira, H., Nedergaard, M., Nicholson, C. Perspectives on spreading depression. *Brain Res. Rev.* 32:215-234, 2000.
51. Martins-Ferreira, H., Ribeiro, L.J.C., Do Carmo, R.J. Threshold determination of spreading depression evoking substances in the retina in vitro. *Braz.J.Med.Biol.Res.* 26:875-877, 1993.
52. Martins-Ferreira, H., Oliveira-Castro, G. Light scattering changes accompanying spreading depression in isolated retina. *J.Neurophysiol.* 29:715-726, 1966.
53. Martin, D.L., Olsen, R.W. **In GABA in the Nervous System: The view at 50 years.** Philadelphia: Lippincott Williams&Wilkins, 2000.
54. Maytal, J., Young, M., Shechter, A. Pediatric migraine and International Headache Society (IHS) criteria. *Neurology*. 48:602-607, 1977.
55. Metcalf, B.W. Inhibitors of GABA metabolism. *Biochem PHarmacol.* 28:1705-12, 1979.
56. Milner PM. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leão. *Eletroencephalog Cil Neurophysiol*, 1958 Nov; 10 (4): 705. Abstract.

57. Mori, S., Miller, W.H., Tomita T. Microeletrode study of spreading depression (SD) in frog retina - General observations of field potential associated with SD. *Jap.J.PHysiol.*26:203-217,1976a
58. Mori, S., Miller, W.H., Tomita T. Microeletrode study of spreading depression (SD) in frog retina – Müller Cell Activity and K<sup>+</sup> during SD. *Jap.J.PHysiol.*26:203-217,1976b.
59. Moskowitz, M.A. The neurobiology of vascular head pain. *Ann. Neurol.* 16:157-168, 1984.
60. Moskowitz, M.A. Neurogenic inflammation in the pathophysiology and treatment of migraine. *Neurology.*43 (3):S16-S20, 1993.
61. Moskowitz, M.A., Nozak, K., Kraig, R.P. Neocortical spreading depression provokes the expression of C-fos protein-like immunoreactivity within trigeminal nucleus caudalis through trigeminovascular mechanisms. *J.Neurosc.*13:1167-1177, 1993.
62. Nascimento, J.L.M. A simple and rapid method to measure aminobutyric acid-transaminase (GABA-transaminase) in the Central Nervous System. Cellular and Molecular Neurochemistry Laboratory, Department of Physiology, University Federal of Pará, Belém City, Pará, Brazil,2008.
63. Nicholson, C., Kraig R.P. The behavior of extracellular ions during spreading depression. The Application of ion-selective microeletrodes. **In Zeuthen T. (eds.)Elsevier.** North Holland: 217-238, 1981.
64. Nicholson, C. Preface II. **In: Migraine: Basic Mechanisms and treatment. Eds. LehmenKühler Alfred; Grotemeyer, Karl-Heinz.; Tegtmeyer, Frank.** Germany, München: Urban&Schwarzenberg, 602, 1993.
65. Nikitina, T.G., Adamson, V.G., Dyskin, D.E., Prokudin, M.V. Determination of Serum Valproic Acid Drugs by Capillary electrophoresis. *Klin. Lab. Diagn.* 11: 15-8, 2006.
66. Olesen, J., Boussier, M.G., Diener, H. The International Classification of Headache Disorders. 2<sup>nd</sup> Edition. *Cephalalgia.*24 (1):1-160, 2004.
67. Oliveira-Castro, G., Martins-Ferreira, H. Deformations and thickness variations accompanying spread depression in the retina. *J. Neurophysiol.* 33, (6):891-900, 1970.
68. Olsen, R.W. GABA. **In K.L. Davis D., Charney J.T.C. and C. Nemeroff (eds.), Neuropsychopharmacology: Fifth Generation of Progress.American College of Neuropsychopharmacology.** Philadelphia: Lippincott Williams&Wilkins.159-168, 2001.
69. Patsalos, P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. *Pharmacol. Ther.* 85:77-85,2000.
70. Pietrobon, D., Striessnig, J. Neurobiology of Migraine. *Nature Rev.* 4: 386-398, 2003.
71. Pucci, V., Mandrioli, R., Raggi, M.A. Determination of Valproic Acid and Divalproex in human plasma by capillary electrophoresis with indirect UV detection. *Electrophoresis.* 24 (12-13): 2076-83, 2003.
72. Puppe, A., Limmroth, V. GABAergic drugs for the treatment of migraine. *CNS Neurolol Disord Drug Targets.* 6(4):247-50, 2007.



73. Ramadan, N.M. Current trends in migraine prophylaxis. *Headache*.47 (1): S 2-7, 2007.
74. Rando, R.R., Coburn, J., Parkinson, D. The differential effects of GABA-transaminase inactivation in the chick retina and brain. *J. Neurochem.* Oct, 39(4):1147-51, 1982.
75. Rasmussen, B.K. Epidemiology of headache. *Cephalalgia*. 15(1):45-68, 1995.
76. Ratnaraj, N., Patsalos, P.N. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. *The Drug Monit.* 20(4):430-4, 1998.
77. Rodrigues, P.S., Guimarães, A.P.O., Azeredo, F.A.M., Martins-Ferreira, H. Involvement of GABA and ach. in retinal spreading depression: Effects of "low calcium-high magnesium" solutions. *Exp. Brain Res.* 73:659-664, 1988.
78. Rodrigues, P.S., Thomaz, T.G., Pinheiro, W.M., Silva, M.C.P. A atividade colinérgica diminui a liberação de ácido gamma-aminobutírico ( GABA) durante a depressão alastrante retiniana? Resumos II reunião An.Fed.Socs.Biol.Exp, pp139, 1987.
79. Rogawski, M.A., **Löscher, W.** The neurobiology of antiepileptic drugs. *Nat. Rev. Neurosci.* 5: 553 -564, 2004a.
80. Rogawski, A., Löscher, W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. *Nature Medicine* 10(7): 685-692, 2004b.
81. Röther, J. Spreading depression and peri-infarct depolarizations. Relevant pathological events in migrânea and stroke? *Nervenarzt.* 71 (2):84-90, 2000.
82. Sanchez-Del-Rio, M., Reuter, U., Moskowitz, M.A. New insights into migraine pathophysiology. *Curr. Opin. Neurol.* 19 (3):294-8, 2006.
83. Scheller, D., Heister, U., Kolb, J., Tegtmeier, F. On the role of excitatory amino acids during generation and propagation of spreading depressions. **In: Lehmenkühler A., Grottemeyer K.H. e Tegtmeier F. (Eds.). Migraine: Basic Mechanisms and Treatment.** Urban & Schwarzenberg. München-Wien-Baltimore: 355-366, 1993.
84. Silberstein, S.D., Collins, S.D. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term safety of Depakote in Headache Prophylaxis Study Group, *Headache.* 39 (9): 633-643, 1999.
85. Silberstein, S.D., Feliu, A.L., Rupnow, M.F., Blount, A.C., Boccuzzi, S.J. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. *Headache.* 47 (4):500-10, 2007a.
86. Silberstein, S.D., Hulihan, J., Karim, M.R., Wu, S.C., Jordan D., Karvois D., Kamin M. Efficacy and tolerability of topiramate 200mg/ml in the prevention of migraine with/without aura in adults: a randomized , placebo-controlled, double-blind, 12-week pilot study. *Clin. Ther.* 28 (9):1482, 2006.
87. Silberstein, S.D., Lipton, R.B. Chronic daily headache. **In: Goadsby P.J., Silberstein s.D. (eds.) Blue Books of Practical Neurology: Headache.** Boston, MA: Butterworth-Heinemann. 201-25, 1997.

88. Silberstein, S.D., Lipton, R.B., Dodick, D.W., Freitag, F.G., Ramadan, N., Mathew N., Brandes, J.L., Bigal, M., Saper, J., Ascher, S., Jordan, D.M., Greenberg, S.J., Hulihan, J. Topiramate Chronic Migraine Study Group. *Headache*. 47(2): 170-80, 2007b.
89. Silberstein, S.D., Lipton, R.B. Chronic daily headache. In: **Goadsby P.J., Silberstein S.D., eds. Blue Books of Practical Neurology: Headache**. Boston, MA: Butterworth-Heinemann. 201-25, 1997.
90. Silberstein, S.D., Neto, W., Schmitt J. Topiramate in migraine prevention: results of a large controlled trial, *Arch. Neurol.* 61: 490-495, 2004.
91. Somjen, G.G. Mechanisms of Spreading Depression and Hypoxic Spreading Depression-Like depolarization. *Physiol. Rev.* 81(3): 1065-1093, 2001.
92. Steiner, T.J. Ethical aspects of headache treatment trials. In: **Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Treatment**. Philadelphia, PA: Lippincott-Raven: 71-8, 1997.
93. Steiner, T.J., Findley, L.J., Yuen, A.W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. *Cephalalgia*. 17(2):109-112, 1997.
94. Strong, A.J., Fabricius, M., Boutelle, M. Spreading and synchronous depressions of cortical activity in acutely injured human brain. *Stroke* 33: 2738-2743, 2002.
95. Van Harreveld, A. Compounds in brain extracts causing spreading depression of cerebral cortex activity and contraction of crustacean muscle. *J. Neurochem.* 3:300-315, 1959.
96. Van Harreveld, A., Fifková, E. Glutamate release from the retina during spreading depression. *J. Neurobiol.* 2:13-29, 1970.
97. Victor, M., Ropper, A.H. Epilepsy and other seizures disorders. In: **Principles of Neurology**. McGraw-Hill, 2005. pp 271 – 301.
98. Vyskocil, F., Kriz, N., Bures, J. Potassium-selective microelectrodes used for measuring the extracellular brain potassium during spreading depression and anoxic depolarization in rats. *Brain Res.* 39:255-259, 1972.
99. Wang, S.J., Huang, C.C., Hsu, K.S. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdala neurons. *Synapse*. 3: 248-55, 1996.
100. White, H.S., Brown, S.D., Woodhead, J.H., Skeen, G.A. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. *Epilepsy Res.* 28:167-169, 1997.
101. Wiedemann, M., Lima, V.M., Hanke, W. Effects of antimigraine drugs on retinal spreading depression. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 353(5):552-6, 1996.
102. Woods, R.P., Iacobini, M., Mazziotta, J.C. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. *N. Engl. J. Med.* 331:1689-1692, 1994.
103. Yacubian, E.M.T. Tratamento Medicamentoso das Epilepsias. Editorial Lemos, São Paulo, 1999.
104. Yasui-Furukori, N., Saito, M., Nakagami, T., Niioka, T., Sato, Y., Fuji, A., Kaneko, S.

Different Serum Concentration of steady-state Valproic Acid and Divalproex in two sustained-release formulations. *Psychiatry.Clin.Neurosci.*61 (3):308-12, 2007.

105. Young, A.B., Chu, D. Distribution of GABA receptors in Mammalian brain: potential targets for drug development. *Drug Dev.Res.* 21:161-67,1990.

## ÍNDICE REMISSIVO

### A

Absorção oral 26, 28  
Acidente vascular cerebral 18, 19, 24, 25, 98, 114, 118, 119, 135  
Acidente vascular encefálico 20, 24, 112, 113, 114, 116, 117, 118, 119  
Alopecia 212, 213, 214, 218  
Alzheimer 1, 2, 3, 4, 5, 6, 7, 32, 36, 38, 40, 41, 43, 46, 193  
Angiomatose 212, 213, 217  
Antiepileptic drugs 47, 48, 71, 72, 73, 75, 77, 78, 79, 80, 83  
Antipsicóticos 42  
Apraxia 32, 33, 129, 205  
Atenção primária à saúde 19  
Atividade de risco 105  
Autoimmune 87, 92, 97

### B

Bahia 101, 152, 155, 159, 160, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 212, 213, 214  
Bainha do nervo óptico 120, 121  
Biodisponibilidade 26, 27, 28

### C

Canabidiol 26, 27, 28  
Cannabis sativa 29  
Cefaleia 107, 134, 135, 221  
Ciclo menstrual 8, 9, 11, 12, 13, 15, 16  
Cognição 15, 17, 41, 44, 45, 87, 127  
Corpo caloso 204, 205, 206, 207, 208, 209, 210, 211  
Corticobasal syndrome 32, 33, 211  
Criptococcose 105  
Crossed cerebellar diaschisis 32, 33  
Custo 43, 131, 159, 160, 161, 162, 164, 169, 170, 173, 176, 177, 178

### D

Demencia 35  
Diagnóstico 24, 35, 36, 37, 38, 39, 40, 45, 46, 86, 89, 91, 92, 94, 100, 107, 109, 113, 118, 120, 121, 129, 131, 133, 134, 135, 136, 137, 143, 150, 153, 158, 159, 160, 161, 178, 179, 181, 182, 183, 186, 190, 192, 194, 195, 201, 203, 204, 205, 206, 210, 213, 216, 217, 221  
Distúrbio de movimento 204  
Distúrbio do metabolismo do cobre 188  
Doença de wilson 188, 190, 192, 193, 194  
Doença neurodegenerativa 2, 99  
Doenças neurodegenerativas 4, 39, 99, 181, 205

## E

Encefalite 87, 92

Endocardite bacteriana 221

Epidemiologia 2, 4, 6, 24, 99, 109, 119, 152, 154, 157, 158, 181

Epilepsia 26, 27, 79, 89, 126, 128, 132, 139, 141, 143, 144, 145, 146, 147, 148, 149, 150, 151, 159, 160, 161, 162, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 198

Epilepsia do lobo temporal 146, 147, 149, 150, 151

Epilepsia refratária 26, 27, 139, 143, 146, 150

Epilepsia resistente a medicamentos 146

Esclerose lateral amiotrófica 93, 94

Esclerose múltipla 181, 182, 184, 185, 186

## G

Genética 126, 189, 196, 212, 213, 230

## H

Hemorragia subaracnoidea 221

Hormônios 9, 15, 201

Hospitalização 19, 24, 36, 112, 113, 163, 176, 177

## I

Indicadores de morbimortalidade 99

Internações 2, 5, 19, 21, 22, 23, 98, 101, 102, 112, 115, 135, 159, 160, 162, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178

## L

Lewy 35, 36, 37, 38, 39, 40, 43

Lobectomia temporal anterior 146, 149

## M

Manifestações clínicas 105, 107, 108, 126, 128, 188, 189, 197, 199

Melanoma 120, 121, 122, 123

Meningite 106, 152, 153, 154, 155, 156, 157, 158

Metástase 121

Migraine 47, 48, 51, 52, 53, 54, 65, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84

Morbimortalidade 2, 3, 5, 6, 98, 99, 152, 153, 154, 157

Movement disorder 32, 87, 104, 204

## N

Nervo óptico 120, 121

Neurologia 17, 32, 86, 88, 99, 119, 126, 134, 136, 181, 188, 196, 211

Neuropatia 134, 135

Neuropharmacology 48, 79



Neuropsicologia 41, 46  
Neurossarcoidose 134, 136

## O

Oligodendroglioma 139, 140, 142, 143, 144, 145

## P

Parkinson 27, 30, 33, 37, 38, 39, 42, 43, 83, 98, 99, 101, 102, 103, 104

Parkinsonismo 37, 38, 100, 188

Pediatria 152, 154, 157, 158

Perfil de saúde 19

Perfil epidemiológico 4, 98, 101, 118, 152, 159, 160, 175, 181, 182, 183

Prevalência 15, 16, 20, 25, 36, 41, 45, 98, 102, 113, 114, 116, 117, 118, 119, 147, 156, 157, 160, 175, 176, 178, 179, 181, 182, 186, 217

Procedimentos cirúrgicos cardiovasculares 221

Psychiatric disease 87

## R

Retina 47, 48, 50, 51, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 68, 72, 73, 74, 75, 76, 77, 79, 81, 82, 83, 84

## S

Segurança 13, 26, 27, 29

Síndrome 18, 35, 36, 45, 87, 89, 94, 126, 128, 129, 130, 131, 132, 133, 153, 160, 161, 178, 179, 180, 189, 194, 195, 196, 197, 199, 201, 203, 204, 205, 206, 207, 210, 211, 212, 213, 216, 217, 218, 219

Síndrome da mão alienígena 203, 204, 206, 207, 211

Síndrome de sturge-weber 212, 213, 216, 217, 219

Síndrome ELA-like 94

Sintomatologia 35, 37, 108, 130, 181, 186

Sonhos 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 211

Spreading depression 47, 48, 49, 50, 51, 71, 72, 73, 77, 78, 79, 80, 81, 82, 83, 84

## T

Terapia antirretroviral 94

Tumor cerebral primário 139, 140

## V

Vasculopatia 134

VIH tipo I 93, 94

 **Atena**  
Editora

**2 0 2 0**